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ABSTRACT
Signature______________________
(Mohammad M. Ataai)
PRODUCTION AND PURIFICATION OF HSV-1 VECTORS
AND ITS USE FOR GENE TRANSFER TO HUMAN CD34+ CELLS
James Brian Wechuck, PhD
University of Pittsburgh
The delivery of therapeutic DNA to patients with genetic or acquired disorders
has evolved into a realistic alternate treatment to surgery, drug delivery, or as an adjuvant
to therapies.  A specific area of this research is to transduce CD34+ cells with therapeutic
DNA containing vectors developed from viruses.  Explanted CD34+ progenitor cells are
exposed to these vectors and then are transplanted to a host.  Despite the positive
iv
advances, major limitations exist in the ability to efficiently transduce cells with current
vector systems.  In addition, if vectors are proven effective at ameliorating disease, the
expense of manufacturing sufficient quantities required to treat large populations of
patients may prohibit their widespread applications.
Our lab utilizes replication-defective herpes simplex virus type-1 (HSV-1) as a
gene delivery vector.  HSV-1 possesses the capability to deliver large or multiple genes
and infects a wide variety of cell types.
In order to optimize transduction of human umbilical cord blood CD34+ cells, I
examined this population for presence and functionality of the three different HSV
receptors required for virus binding and entry.  Optimal transduction efficiencies of 75%
were obtained by systematically varying vector concentration and adsorption time.
Additionally, several vector constructs were developed in order to examine the effects of
various promoter systems and additional gene deletions on gene expression and vector-
associated toxicity.
Throughout these studies we were confronted with the difficulty of obtaining
sufficient amounts of high quality vector needed for testing the efficacy of HSV-1 vectors
in various applications.  To further improve the vector yield, I examined the effect of
temperature and media conditions on the stability of an HSV-1 vector.  Applying a
temperature shift to production conditions resulted in increased vector yields that
remained stable at peak levels in cultures incubated at 33°C rather than 37°C.
To enhance vector recovery, alternative purification strategies were examined.  A
two-stage tangential flow filtration system coupled to a chromatography step was
vdeveloped to isolate vector from large debris such as cells and smaller molecules such as
protein and DNA.  This new system for vector concentration and purification proved
superior to the standard protocols currently in use.
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11.0  BACKGROUND
1.1  Gene Therapy
1.1.1  Introduction
Delivery of therapeutic DNA, RNA, or protein to various tissues for the treatment
of a wide range of disorders is emerging as an important route to therapeutics.  Gene
transfer to human cells has shown great promise for the prevention and/or treatment of
both genetic and acquired diseases.  Genetic diseases such as Adenosine Deaminase
Deficiency (ADA)(1,2)∗, Muscular Dystrophy (MD)(3-6), Cystic Fibrosis (CF)(7,8),
Alzheimer’s Disease (AD)(9-11), Parkinson’s Disease (PD)(12-15), etc. that arise due to gene
defects significantly affect the human condition and mortality, and have been examined
for treatment by gene therapy.  Researchers have isolated mutated genes that result in
these disorders and delivering the correct gene sequences to the appropriate cells is one
potential treatment.  Another possibility is to deliver antisense RNA or a gene of which
its product will block or degrade the mutated gene’s product(16-18).  For acquired disorders
such as cancer, other types of gene therapy strategies have been studied.  Since
elimination of these cells is preferred, the transfer of a gene coding for a cytokine to
stimulate an immune response, or a gene that is toxic itself (suicide therapy) or in
combination with conventional radio/chemical therapies have great potential(19-21).
According to data last updated 11/19/01 by the Recombinant DNA Advisory
Committee (RAC) at the National Institutes of Health (NIH), Bethesda, MD, there are
500 clinical protocols that had been approved in the USA for human gene transfer.  Out
                                                 
∗ Parenthetical references placed superior to the line of text refer to the bibliography
2of those approved, 458 were for therapy, 40 were for marking, and 2 were non-
therapeutic.  Sixty nine percent of therapy protocols were for the treatment of cancer,
12% were for genetic diseases such as cystic fibrosis, 8% were for infectious diseases
(mainly AIDS), and 11% for other disorders.  This information is available online at
http://www4.od.nih.gov/oba/rac/documents1.htm.
There are two main types of vehicles that are used to transfer genes into cells:
non-viral and viral.  Non-viral methods involve transferring DNA to cells by a variety of
methods such as naked DNA or as complexes with calcium chloride or lipid-based
reagents.  These types of vehicles account for 20% of the approved clinical protocols.
The remaining 80% of clinical protocols use vectors developed from viruses(22).  Viruses
have been extensively studied for decades in order to further the understanding of gene
expression, DNA replication, virus pathology, and human disease.  Basic understanding
of how viruses function has greatly enhanced the advancement of genetically
manipulating viruses in order to utilize natural parasitic systems as vehicles, or vectors,
for efficient delivery of the therapeutic DNA.  The main examples of genetically
engineered viral vectors include; Retrovirus (MMLV and Lentivirus), Adenovirus,
Adeno-Associated Virus (AAV), and Herpesvirus.
In developing or determining the appropriate vector for eventual in vivo use,
several points must be considered.
1. Tropism- If using viral vectors, the natural tropism of the virus must be considered.
Some viruses only infect specific cell types efficiently while others infect many cell types
(ubiquitously).
32.  Infectivity- (related to tropism) In some applications, an extremely high number of
particles are needed to achieve the desired transduction numbers.  Each delivery vehicle
differs in the number and concentration of particles that can be produced.
3.  Immunity- Immune responses can result from transduction with some viruses or DNA
that may lead to the transduced cell being eliminated.  Immune responses may also
inhibit redosing due to cellular and/or humoral responses.  Causes of these include viral
proteins expressed, transgene, or contaminants such as proteins or DNA in the stock.
4.  Expression- Therapeutic expression of a transgene may be needed transiently, required
long-term, or regulated.  This is dictated by the viral or plasmid background as well as the
promoter system used.  Episomal versus integrated genes can also affect the transgene-
expressing cell numbers as well as the level of expression.
5.  Capacity- The size of the transgene to be delivered must be within the capacity of the
vehicle used.  Some vectors can support large or multiple genes while others are not able
to do so.
1.1.2  Non-Viral Vectors
Several methods have been developed to transfer genes to mammalian cells by
non-viral vectors.  These techniques include calcium phosphate co-precipitation,
liposome complexation, microinjection, gene-particle bombardment, electroporation, and
receptor-mediated gene transfer(23-26).  Interest in this area has developed due to potential
problems faced by viral vectors that include viral tropism, packaging capacity, toxicity
and/or immune responses, and production limitations.  Non-viral vectors have been
limited by their low efficiency and ability for direct in vivo use(27.28).  In addition, immune
4responses have been a problem in some instances and long-term gene expression has
been variable.
1.1.3  Retroviral Vectors
The retroviridae family are small, enveloped RNA viruses whose virions vary in
size from 80-130 nanometers (nm).  Their genome size ranges from 3.5-9 Kb and carry
two copies of a (+) single-strand RNA genome in each virion (for a review see Fields(29)).
An important feature of these viruses is their ability to reverse-transcribe and integrate
into host cell DNA, thus resulting in its own genome permanently residing in
subsequently produced daughter cells.  Most retroviral infections do not kill the host cell,
but have been shown to possess tumorigenic properties.  This can result from integrations
that disrupt cellular growth control genes, the activation of cellular oncogenes, or viral
gene products that are oncongenic themselves.
Once integrated, the provirus is transcribed by cellular transcription factors
directed by the viral promoter.  Transcription results in one primary messenger RNA
(mRNA) that is the genome for new virion production and codes for proteins upon
splicing, translation, and proteolysis.  The viral genome consists of 3 major genes: viral
core proteins (gag), the polymerase (pol) genes which include reverse transcriptase and
integrase enzymes, and envelope proteins (env).  As virions are produced, they are
assembled with specific proteins into capsids and eventually bud from the host cell.  The
genomic RNA has a packaging signal (ψ) at the 5’ end of gag and the 3’ end of the splice
donor that is recognized by viral proteins to ensure that only viral RNA is packaged into
virions.
5Retroviruses were among the first viruses to be developed into gene therapy
vectors.  Retroviruses are divided into three subfamilies according to their
pathogenicities: oncovirinae, lentivirinae, and spumavirinae.  Although several virus
groups have been examined as vectors, only two [Moloney murine leukemia oncovirus
(MMLV) and HIV-1 Lentivirus] are extensively used for gene therapy research.
1.1.3.1  Moloney Murine Leukemia Viral Vectors
The initial retroviral vectors were derived from MMLV and have been most
prevalently used to date(30,31).  There are two types of MMLVs, ecotropic and
amphotropic.  The major difference between these two is their infectable host cell range,
or tropism, due to a variation in their surface binding protein (SU).  Since ecotropic
MMLVs can only infect rodent cells whereas the amphotropic form can infect human,
rodent, and other cell types, the latter are primarily studied for human gene transfer(32-34).
In order to engineer safe MMLV vectors for gene therapy, the virus was rendered
replication defective by deleting the gag, pol, and env genes and replacing them with a
transgene(35).  In order to produce vector stocks, the deleted viral genes but not the
packaging (ψ) signal, are provided in trans in packaging cell lines.  This ensures that only
vector RNA can be packaged and released.  In order to minimize the potential for
replication competent viruses (RCV) during production, the gag and pol genes are
separated from the env gene in the packaging cell line.  For vector stock production,
packaging cells are grown in culture and then transfected with the desired vector plasmid
construct.  The desired virus is produced and assembled into particles that bud from the
cells.  The supernatant is harvested, purified, and concentrated to make vector stocks.
This stock can be tested for wild-type virus and then used to infect target cells.
6After an MMLV vector binds to the appropriate cellular receptor, viral uptake
occurs by membrane fusion.  Upon this entry, the capsid is released from the viral
envelope.  The capsid carries viral RNA, RT, IN, and a cellular transfer RNA (tRNA).
The genome is reverse-transcribed into double-stranded DNA using the tRNA as a primer
and the RT enzyme.  During this conversion, unique long terminal repeated (LTR)
sequences are present at each end of the DNA.  This complex is then transported to the
nuclear membrane where it requires cell division to obtain entry.  Upon cellular division,
the nuclear membrane is broken down and thus the complex is able to enter the nucleus.
Integrase then mediates integration of the viral DNA to a random site of the host genome
and is maintained by all daughter cells.
There are currently several limitations of MMLV vectors.  First, vector stock
titers have been limited to 107 pfu/mL(36,37).  Second, the virus is limited to only infecting
cells that possess a receptor for its lone glycoprotein(32).  Third, the inability to integrate
into non-dividing cells such as neurons or stem cells has limited their use(38).  Fourth, the
virion is limited in the size of insert transgene that can be inserted into the genome.
Lastly, the length of transgene expression in infected cells has been variable(39).
1.1.3.2  Lentiviral Vectors
The main primate infecting lentiviruses studied for vector use are the human
immunodeficiency virus types 1 and 2(40).  These viruses are tropic for lymphocytes in
particular and cause AIDS in humans.  Lentiviruses have similar genomes to other
retroviruses but encode numerous additional spliced RNA products (for a review, see
Fields(41)).  HIV vectors have received much attention recently due to their ability to
reverse transcribe and integrate into non-dividing cells.  Matrix protein (MA), a structural
7protein present in the virus particle anchors the envelope proteins into the virion and has
a nuclear localization signal that targets the viral DNA-protein complex to the
nucleus(42,43), thus not requiring division as MMLV does.  Another protein, Vpr, in
addition to integrase has also been suggested to contribute to integration into non-
dividing cells.
A variety of HIV based vector production systems have been engineered(44).  As
with other retroviruses, the packaging signal, the primer binding site, a polypurine tract,
and LTR sequences are present in the transfer construct.  Several sustained or transient
production schemes exist based on producer cell lines or co-transfection with one or two
packaging constructs and a transfer plasmid.  The main goal is to produce high levels of
vector, while eliminating recombination that could produce replication competent viruses
(RCVs).
The limited natural tropism of HIV had restricted the use of these vectors as a
vaccine to patients already infected with HIV to provide protection to uninfected CD4
cells.  To expand vector tropism, envelope genes from other viruses have been used to
make a pseudotyped vector with a wider host range.  Successful vectors have been
engineered with the Vessicular Stomatitis Virus glycoprotein G (VSV-G) or the
amphotropic MMLV env gene(40,45).  An added advantage that these vectors have over
MMLV is the ability for high-level gene expression using the powerful Tat/LTR
promoter combination found in HIV.  Recent experiments have shown the ability of
lentiviral vectors to maintain long-term transgene expression in vitro and in vivo(46,47).
HIV vectors are currently limited to titered stocks of 1×108/mL(48).  Additionally, its host
range is limited to the envelope that is provided in the packaging cell line.  The limit of
8transgene insert is approximately 9 Kb.  A major concern of working with these vectors is
its reverting to a replication-competent vector.
1.1.4  Adenoviral Vectors
Adenoviridae are class I, non-enveloped, DNA viruses. The linear, double-
stranded genome is approximately 36-38 Kb with a virion diameter is 70-90 nm (for a
review, see Fields(49)).  Adenoviruses (Ad) are subgrouped A through G, originally
classified by hemagglutination patterns.  A natural advantage of Ad is that it has been
shown to infect a wide variety of cell types in culture.  The subgroup that has been
extensively studied for vector use is the non-oncogenic C types 2 and 5, which cause mild
respiratory diseases in humans.  Ad binds to the coxsackie and adenovirus receptor
(CAR) on cell surfaces, interacts with clathrin-coated pits and is endocytosed.  In the
endosome, the pH drops and the virion is released into the cytoplasm where the capsid is
then transported by microtubules to the nuclear membrane and the genome enters the
nucleus.
The viral genes are classified as early-E (before DNA replication) and late-L
(after onset of DNA replication).  The E1 region of the genome is initially transcribed by
cellular transcription factors and its gene products, E1a and E1b, transactivate E2–E4.
The E2 gene products include a DNA binding protein (E2a) and viral DNA polymerase
and terminal protein (E2b).  The E3 region has been found to be non-essential for growth
in culture but is involved in evading host defense mechanisms by interacting with major
histocompatibility complexes (MHC).  E4 gene products are involved in a number of
functions including the regulation of late promoter activation and viral DNA replication.
The late genes L1-L5 code for the structural proteins of the virion.
9Adenoviral vectors are constructed by the deletion of a combination of early
genes(50).  The vector must retain the 5’ ITR and packaging signal.  The deletions can
then accommodate transgenes of similar size that have a promoter and a polyadenylation
signal.  A variety of ubiquitous promoters have been tested such as the Ad major late
promoter(51) and the human cytomegalovirus immediate-early promoter (HCMV-IEp)(52).
Drug regulatable(53) and tissue-specific promoters(54) have also been used in Ad vectors.
In order to propagate these vectors, complementing cell lines are needed that contain the
essential deleted genes, such as 293 cells(55) that express E1a and E1b.  After vector
infection of the complementing cells, the virus is harvested.  The cells are broken open
and the virus is separated based on centrifugation and/or chromatography(56,57).  The Ad
particles are stable over a wide range of pH and temperature compared to enveloped
viruses and can result in 1011 pfu/mL or higher stocks.  The major disadvantage presently
associated with Ad vectors is the immune response to either the expression of low levels
of viral genes or contaminating viral proteins associated with the viral preparations(58,59).
This latter is evident even in gutless vectors that have no viral genes remaining.  The
presence of helper viruses is a concern with this vector.  These problems thus result in
only short-term expression of the viral transgene.  Another concern is that of generating
replication competent viruses during propagation.
1.1.5  Adeno-Associated Viral Vectors
Adeno-Associated Virus (AAV) is a non-enveloped, class II parvovirus.  Its
genome is a single-stranded linear DNA of ~5 Kb, with a virion diameter of 18-26 nm
(for a review, see Fields(60)).  There are 4 human serotypes (1, 2, 3, and 5).  AAV2 has
been the most prevalently studied.  AAV is not known to cause any disease in humans,
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although it has been isolated in people with Ad infections.  AAV also integrates its
genome site specifically into the host DNA.  These features have made AAV an attractive
option for vector gene transfer.
AAV infects permissive cells by binding to heparan sulfate and subsequent
endocytosis.  As with Ad, the virion escapes during endocytolysis and the genome is
transported into the nucleus.  There are two outcomes of an AAV infection depending on
the presence of a helper virus.  If there is no helper virus (such as Ad or Herpesvirus),
AAV will integrate as head to tail dimers of its genome in the host DNA or can be found
as episomes.  If the host cell is co-infected with a helper virus and AAV, AAV can
replicate.
The AAV genome has inverted terminal repeats (ITRs) at both ends.  The viral
DNA transcribes two genes: rep (replication) and cap (capsid).  Rep has two promoters,
one internal.  The first promoter encodes an unspliced Rep78 protein and a spliced Rep68
protein.  Rep78 and Rep68 have a number of properties including aiding in viral DNA
replication, processing, transcription, and integration.  The internal promoter transcribes
an unspliced Rep52 and a spliced Rep40 protein.  Rep52 and Rep40 are required for
accumulation of single-stranded DNA copies during productive infection.  The cap gene
is spliced to translate the three structural proteins of the virion VP1, VP2, and VP3.
AAV vectors are created by the deletion of some or all of the internal genome of
the virus while minimally leaving the ITRs with a promoter and a transgene inserted
between the ITRs(61,62).  In order to propagate this vector, the rep and cap genes must be
provided to vector infected cells(63,64).  Packaged AAV vectors are extremely stable and
can undergo several purification procedures without substantial losses resulting in vector
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stocks of 1×1011 total infectious units/mL (TIU/mL).  One noticeable disadvantage of
AAV vectors is that they integrate much less frequently and not site specific as wild-type
virus does due to the lack of Rep products(65).  This can cause the need to use high
numbers of particles for adequate transduction.  In vivo AAV vectors may evoke immune
responses that results in the inability to redose(66).  Another problem is that of limited (5
Kb) transgene capacity.
1.1.6  Herpesvirus Vectors
There are two main classes of HSV-1 vectors being researched, amplicons and
genomic.  Amplicons were observed as replication defective particles naturally
propagated during infections, in particular ones generated from high MOI cultures(67).
These particles have a viral origin of replication and a packaging sequence in addition to
various repeated sequences, but lack several viral genes required for replication(68).
Amplicon plasmid vectors have been developed based on this observation(69,70).
Therapeutic genes cloned into plasmids can be packaged into virions due to the presence
of the viral original packaging signals and propagated in bacteria.  Packaging requires the
coinfection of the amplicon with either a helper herpesvirus or complementing plasmids.
A major problem is that stocks may be contaminated with helper virus and are limited to
low-titer production(70,71).  The genomic vectors are either replication competent or
replication defective.  Those that are developed by the deletion of the expression of one
or more non-essential viral genes such as ICP34.5(72) or Ribonucleotide Reductase
(ICP6)(73), which affect neurovirulence, are replication competent and primarily used to
deliver genes to neurons for CNS disorders.  Another application for this vector is the
destruction of tumor cells since they are extremely toxic to dividing cells.  The second
12
type of replication-defective vector is based on HSV genomic manipulation to delete one
or both of the essential immediate early (IE) genes ICP4 and ICP27(74-76).  A
complementing cell line that expresses these deleted essential genes must be made to
propagate the vector.  Vector production and infected cell toxicity are often inversly
related to the number of IE genes deleted(77,78).  In addition, approximately half of the 84
known genes are dispensable for growth in culture(79) and thus vectors are able to carry
large or multiple transgene inserts due to the further deletion of these non-essential
sequences.  HSV-1 has been shown to efficiently infect most cell types, including
nondividing cells, in culture(80,81) and has a natural property to become latent in neurons.
The viral genome remains episomal in infected cells and shown to be maintained in
neurons(82,83).  Various viral promoters are able to transiently express transgenes in the
vector(84,85).  In neurons, latency-active promoter systems have demonstrated long-term
transgene expression(86,87).  Disadvantages of HSV-1 vectors include either cytotoxicity
from undeleted IE gene expression in non-neuronal cells or current low titers achieved
from vectors crippled in multiple IE and other genes that show diminished toxicity.
Purification of defective interfering particles in vector stocks is also currently lacking.
1.2  Herpesviridae
1.2.1  Classification of Herpesviruses
Herpesviridae are enveloped, class I, double-stranded linear DNA viruses(88).  The
genomes range from 120-200 Kb and its virion diameter is 150-200 nm.  Herpesviruses
are grouped as α, β, or γ subfamilies according to infection characteristics and classed A-
F according to sequence arrangements of their genomes.  Eight different human
herpesviruses have been isolated.  The α subfamily includes Herpes simplex virus (HSV)
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types 1 and 2, and Varicella-Zoster virus (VZV).  The β  subfamily includes
Cytomegalovirus (CMV), Human Herpesviruses (HHV) 6 and 7.  The γ subfamily
includes Epstein-Barr virus (EBV) and HHV 8.  Several herpesviruses have been studied
for vaccines, such as EBV, VZV, and HSV-2, but HSV-1 has shown the most promise for
gene transfer(89,90).  Some important characteristics of HSV-1, which is an α virus,
include a large genome of 152 Kb, ease of gene manipulation, a wide host cell range,
short reproductive cycle, rapid spread in culture, a natural tropism for neurons and the
ability to become latent in these cells(79).  β viruses have a long reproductive cycle and
progress slowly in culture.  γ viruses have tropism for lymphocytes and become latent in
this tissue.
1.2.2  HSV-1 Structure
A lipid bilayer membrane, obtained from the infected cell host during budding,
surrounds the virus particle(79).  This envelope contains at least 10 different viral
glycoproteins integrated in the lipid bilayer that function in binding to a variety of cell
surfaces and aid in membrane fusion.  The tegument is a matrix of at least 6 different
proteins that connects the capsid to the envelope.  These proteins include VP16, an
Immediate Early (IE) viral gene transactivator, and UL41, a virion host shutoff protein
(vhs) that induces degradation of cellular mRNA, which aid the virus in efficiently
infecting and replicating in cells.  The nucleocapsid is an icosadeltahedron consisting of
at least 5 proteins, with 960 copies of the major one, VP5, forming the hexamers and
pentamers making up the shell.  Inside the capsid is 152 Kb double-stranded linear DNA,
seen as a torroidal shape in electron micrographs.  The genome is designated as class E
being that it is divided into a Unique Long (UL) and Unique Short (US) region, with the
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termini of each possessing inverted repeat sequences which make the regions reversible
in orientation.
1.2.3  Biology of HSV-1
HSV-1 infection of susceptible cells involves attachment to ubiquitous cell
surface glycosaminoglycans followed by secondary attachment to specific receptors.
During initial adsorption, HSV-1 glycoproteins gB and gC bind to surface expressed
heparan sulfate (HS) as a quasi-coreceptor(91-93).  Next, HSV-1 gD binds to one of two
cellular receptors identified as Herpesvirus entry mediators (Hve) A and C.  The gD
receptor HveA(94-97) has been characterized as a member of the TNF/NGF receptor
superfamily.  The known natural ligands of HveA are LIGHT and lymphotoxin α, both of
which are structurally similar to TNF(98,99).  The second major HSV-1 receptor, HveC
(also termed nectin-1 or prr1), is a transmembrane cellular adhesion molecule(100,101) and
a member of the immunoglobulin (Ig) superfamily(95,102,103).  In addition, gD can interact
with 3-O-sulfotransferase (3-OST)-modified heparan sulfate on the cell surface(104).  It is
one of these interactions which is believed to trigger fusion of the virus envelope with
cell membranes resulting in virus entry.
The envelope fuses (independent of pH) at the cell membrane and the virion
enters the cell.  The tegument proteins and capsid are released into the cytoplasm.  The
capsid is transported via microtubules to the nuclear pores where the DNA is injected into
the nucleus through the pores and circularizes.  At this point, viral gene expression
proceeds through a highly regulated temporal cascade.  Viral IE protein transcription is
initiated by VP16, after which a cascade of Early (E) and Late (L) gene expression
follows, ending with virion production, packaging, and release, and host cell death.  In
15
this cascade, the IE genes are generally transcription modulators, the E genes are
regulated by the IE expression and are responsible for DNA replication.  The L gene
expression occurs following viral DNA replication and requires IE and E gene
expression.  The L genes are comprised mainly of structural proteins for the virions.  It
has been shown that approximately half of the viral genes are non-essential for viral
production in culture.
 There are 5 IE genes (ICP0, ICP4, ICP22, ICP27, ICP47), also designated α
genes, that are transactivated and expressed immediately upon infection(105-108).  These IE
genes are distinguished by the presence of TAATGARAT sequences in their promoters,
which are recognized by VP16 and cellular factors octamer binding factor-1 (Oct1) and
host cell factor (HCF).  ICP4 is an essential gene for replication that is present in two
copies, one at each US terminal repeat region.  It is a major regulatory protein that acts as
a repressor and activator of viral genes.  In studies of viruses deleted for ICP4, the
expression of E and L genes are greatly reduced while the remaining IE genes are
overexpressed(109,110).  ICP27 is essential and present in 1 copy.  ICP27 has been shown to
aid in E and L gene expression(111-113).  ICP0 is non-essential and present in two copies in
the inverted repeats, one each in the internal and external regions flanking the UL.  ICP0
is a powerful transactivator of viral promoters(114,115) and ICP0 mutants grow at reduced
rates in culture(116,117).  It is also required for reactivation from latency in neurons.  ICP22
is non-essential and ICP22 mutants have shown to be slightly reduced in viral yield in
culture.  ICP22 has been shown to affect late gene expression(118) and regulates stability
and splicing of ICP0 mRNA(119).  ICP47 is non-essential and inhibits immune response in
vivo by blocking the presentation of MHC class I antigen peptides(120).
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The next class of genes expressed is the Early (E), or β genes, which are
dependent upon efficient IE expression as mentioned above(109,110,116,117,121,122).  The
products of this class are mainly enzymes that are involved in DNA replication.
Replication involves a rolling circle mechanism that produces head-to-tail concatomers of
the viral genome.  There are three origins of replication in the genome, one in the UL and
two in the US region
(79).  E genes include proteins such as Thymidine Kinase (TK or
UL24), dUTPase (UL50), large and small Ribonucleotide Reductases (UL39 and UL40),
and DNA polymerase (UL30).  TK is non-essential for growth in culture and its activity
differs from cellular TKs.  Upon addition of drugs such as Acyclovir (ACV) or
Ganciclovir (GCV) to infected cells, TK converts them to 3’ phosphorylated nucleotide
analogs, which block subsequent nucleotide addition during DNA synthesis and thus
prevent cellular DNA replication and cause cell death.  The activated nucleotide analogs
can pass through gap junctions to neighboring cells and likewise cause cell death,
commonly referred to as the “bystander effect”.  Thus, HSV-TK has proven of great use
in cancer therapy applications and numerous viral and non-viral approaches have been
used to deliver HSV-TK to kill tumor cells.  ACV or GCV is used to control reactivation
of wild-type viral infections in patients.
The final set of genes expressed is designated as Late (L) or γ, which are
primarily virion structural proteins.  Late expression requires DNA replication(123,124) in
addition to the IE gene products.  Examples of L proteins include the major capsid
protein ICP5, tegument proteins VP16 and UL41, the glycoproteins of the viral envelope,
and a protease, UL26, required for packaging of DNA into capsids.  DNA containing
capsids with tegument proteins bud from the nucleus to the ER and obtain an envelope.
17
Two methods of viral release are postulated(79).  In one, the virion de-envelopes and
enters the golgi where it reacquires a new envelope with mature glycoproteins.  The virus
is then transported to the cell membrane and released.  The second directly transports the
virion with envelope from the ER through the golgi where the immature glycoproteins
present in the original envelope are processed.  Then the virion is transported to the cell
membrane to be released by exocytosis and/or cell lysis.
1.2.4  Latency
A wild-type HSV-1 infection in vivo begins with attachment to an epithelial skin
cell(125,126).  Upon infection, the lytic cycle occurs as previously described(127-129).  After
replication and release the virus spreads and invades local nerve endings.  The virus is
then transported to the cell body of the sensory ganglion.  The cascade of viral gene
expression in neurons begins as the lytic cycle does but IE gene expression is soon
repressed and the virus enters a latent state.  In this state, the genome is circular and non-
replicating.  During latency the normal cascade of gene expression is silenced, however,
the latency-associated transcript (LAT) is expressed during this time and is the hallmark
of HSV latency(130-132).  LAT is present in two copies, one each in the terminal repeat
flanking the UL.  Following splicing of the primary LAT, two overlapping, nonlinear
introns are produced of 2.0 and 1.5 Kb in length and accumulate in the neuron(133,134).
The functions of the LATs are not known.  Mutant viruses deleted of LAT replicate and
establish latency although they appear to be reduced in the ability to reactivate(135-137).
1.2.5  Current Replication-Defective HSV-1 Vectors
Replication-defective genomic HSV-1 vectors were initially developed by the
deletion of both copies of the ICP4 essential gene(109).  The propagation of this vector in
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vitro requires the protein be provided in trans.  A complementing cell line was developed
to provide this gene.  However, this vector was toxic to both primary neurons and non-
neuronal cells in culture due to the over-expression of other IE genes in ICP4 mutants.  A
second-generation vector was deleted for the essential ICP27 gene, which is required in
trans as well(74-76).  This vector showed a decrease in toxicity.  From this background,
vectors have been developed with additional mutations in a combination of the remaining
three IE genes (ICP0, ICP22, ICP47), with toxicity, production, and transgene expression
decreasing in general as the number of IE deletions increases(77,78,138).  The deletion of all
IE genes results in the inability of viral gene expression in noncomplementing cells
(except for LAT in certain instances).  The host protein shutoff gene, UL41, has also been
deleted in some backgrounds, which may aid in infected cell survival(139-141).
1.3  Stem Cells
1.3.1  Introduction
Cell-based therapy is the attempt to treat human disease by replacing or repairing
the biological function of damaged tissues or organs with donor cells(142).  Traditionally
this has been performed by organ or blood transplantation.  Research in this area has
begun to turn its attention toward the use of stem cells(143-145).  Stem cells of the blood(146)
and skin(147,148), which have been studied for decades, have shown the ability to
repopulate and/or repair their respective tissue under certain conditions.  Recently stem
cells have been identified in other tissue including muscle(149,150) and brain(151) that have
the ability to become other cell types than that from which they were isolated.
The definition of a stem cell varies from each particular research area or
application.  One set of researchers has outlined a theoretical hierarchy based on the
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limiting degrees of differentiation, proliferation, and the self-renewal potential of stem
cell types(142,144,146).  The most primitive cells are named totipotent.  Totipotent cells such
as embryonic tissue, or zygotes, are able to give rise to cells of every lineage of the body.
In adult tissue, the most primitive stem cells are defined as pluripotent.  These cells are
able to give rise to cells of one or more particular tissue types, but not all, as with
totipotent stem cells.  Examples of this type are muscle derived stem cells that are able to
repopulate the hematopoietic system(149,150), mesenchymal stem cells that can become
osteoblasts, fibroblasts, myoblasts, and other cell types(152), or hematopoietic cells that
can incorporate into muscle(153) or endothelium(154).  The third type of stem cell is
described as multipotent.  These cells are less primitive and are committed to becoming
various cell types of a predetermined tissue.  Multipotent cells can be exemplified by
certain hematopoietic cells that, as opposed to the pluripotent cells, can only give rise to
the different types of blood cells.  As all stem cells proliferate, mature, and differentiate,
their daughter cells approach a terminal state that can no longer develop into new cell
types.  Some researchers have suggested that certain cells may be able to dedifferentiate
or trans-differentiate(144,146).  This has not been formally proven and may be merely a
matter of definitions or contaminating cell populations.  An important feature of all three
classes of stem cells is the ability for self-renewal, as well as the differentiating and
proliferating potential each possesses.  These features make stem cells very promising for
many therapeutic applications.
Physical definitions also exist for describing and determining stem cell potential
and have been extensively studied in the context of the hematopoietic system.  One
important method for determining primitive stem cells capable of reconstituting a
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hematopoietic system is by transplantation of a population into a lethally irradiated SCID
(severe combined immuno-deficient) mouse(155-161).  Survival of the mouse is dependent
upon a reconstituted hematopoietic system derived from the donor cells.  A comparative
population of cells are then removed from this surviving mouse and transplanted to
another lethally irradiated SCID mouse.  If at least this secondary mouse and possibly
any other serially treated mice from each previous mouse survive, the originally
transplanted cells are considered to possess among them SCID repopulating cells (SRC)
or primitive hematopoietic stem cells.  Experiments of this nature have been performed
with cells derived from umbilical cord blood, bone marrow, peripheral blood(160), and
recently from cells of tissue such as muscle(150).  Initially all cells of the marrow or blood
were used to obtain repopulating ability, but within the past several years researchers
have begun to separate out and characterize various populations within these tissue.  This
can be achieved through the use of cell surface markers, which are identified by antibody
labeling(157,162).  One of the earliest and most useful markers for hematopoietic cells is
CD34.  This marker is present on a wide population of primitive and lineage committed
cells.  Other surface markers have been discovered that can be of some use in further
classifying sub-populations within the CD34+ cells(163).
The absence of some or all surface markers associated with further differentiated
states (lineage markers) on cells of the 34+ population has been shown, in general, to
indicate a more primitive cell with higher SRC or proliferative potential(164-166).  Some
examples of common subsets of cells that are studied by researchers searching for
enrichment of primitive hematopoeitic stem cells include i) CD34+/CD38- or ii)
CD34+/Lin- (a cocktail of lineage markers).  Two new subsets of CD34+ cells have
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recently been studied, CD34+/KDR+(167) and CD34+/AC133+(168-170).  Populations such as
these have been isolated and transplanted in limiting numbers to SCID mice to verify the
presence of SRC cells.  Another isolation method for obtaining pluripotent stem cells
from bone marrow as well as other tissue has been developed.  This method identifies
stem cell populations as a small sub-population that extrudes the Hoescht 33342 dye and
has been referred to as the “Side Population” or “SP”.  These cells have been shown to be
CD34-(171,172).  Recently, researchers have also begun to study the CD34- population of
blood cells for the presence of SRCs.  These various populations are commonly purified
by fluorescence activated cell sorting (FACS).
The previous method of determining SRC potential is based on in vivo assays.
Attempts to characterize hematopoietic stem cells by in vitro assays have also been
developed(173).  The "Colony Assay"(174,175) involves culturing a small number of cells in a
cytokine-supplemented media to allow the cells to expand.  This is done in
methylcellulose to keep proliferating cells together in a colony so that the daughter cells
are in a confined area with the cell they originated from.  After expansion for up to 2
weeks the colonies are scored according to the phenotype they represent, such as
erythroid, granulocyte/monocyte, or a mix.  The cell that originates each colony is termed
a "Colony Forming Cell (CFC)".  Another commonly used method, the "Long-Term
Culture Initiating Cell (LTC-IC) Assay"(176,177) was developed to identify the presence of
more primitive cells than the colony assay.  The cells to be assayed are cultured in serial
dilutions on a supportive feeder layer of irradiated bone marrow stromal cells.  The
cultures are maintained for 5 weeks.  By this time, more committed progenitor colony
forming cells have proliferated, terminally differentiated, and died.  New cells and
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colonies growing are from LTC-ICs.  The cells are then harvested and plated to
methylcellulose cultures.  After 2-3 weeks, the colony numbers are assayed.  It is
important to realize that identifying and maintaining pluripotent stem cells (PSCs) in
culture is difficult.  They are typically quiescent in their natural environment and divide
only when needed (signaled by local cues).  Attempting to culture these cells without
causing death or differentiation to a particular lineage is an important research area
currently being explored(178-184).  This ex vivo expansion of hematopoietic stem cells so as
to expand to all lineages of the blood, while self-renewing the primitive stem cells can be
used to prepare stocks that aid bone marrow transplant (BMT) patients.  Ex vivo
expansion will save a great deal of time (several weeks) that is needed before total
engraftment occurs in a body after a traditional BMT.
1.3.2  Endothelial Progenitor Cells
One example of using stem cell differentiation and homing for treatment of
disorders is that of endothelial progenitor cells (EPCs).  Several reports have
demonstrated the presence and potential utility of EPCs in adult blood(168,185,186),
including the treatment of ischemia by the enhancement of neovascularization(187-189) or
the enhanced endothelialization of vascular grafts(190).  Due to the evidence that tumors
cannot grow greater than 1-2 mm3 without newly formed vascular networks feeding it,
interest has grown in developing antiangiogenesis agents as a potential treatment(191-193).
This newly developed vascular network may be made up partly of EPCs from blood
and/or marrow.  A focus on EPCs as targets in anti-angiogenesis has been briefly
examined. Ito et al.(194) isolated EPCs (adherent cells from human peripheral blood) and
showed that they, as opposed to human umbilical vein endothelial cells (HUVECs), are
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sensitive to angiostatin, which is used to treat cancer by inhibiting endothelial cell
proliferation.  This implies that angiostatin and possibly other related drugs control tumor
development by inhibiting recruitment or development of EPCs for the developing
vascular network.  A potential therapeutic use for the differentiation and homing of EPCs
is antiangiogenesis through delivery of a toxic gene to a tumor.  This can be
accomplished by harvesting CD34+ cells from a patient with a solid tumor and
transducing the cells with a vecor that contains the toxic gene.  The cells, when
implanted, would deliver this gene to the tumor, resulting in tumor death(195).
1.3.3  Gene Transfer to Stem Cells
Manipulation of the genetic make-up of stem cells could be used to treat disease
by infusing the patient's own transduced (corrected) stem cells back into the afflicted
individual, thus avoiding the rejection of foreign donor cells(143,196).  Subsequent cellular
homing and/or differentiation and expression of the introduced transgene would correct
the genetic deficit.  This approach has been used to correct the SCID-X1 disorder in
human patients by transducing CD34+ bone marrow cells with a Moloney murine
leukemia virus (MMLV) vector carrying the γc  cytokine receptor gene(197).  Growth
factor or morphogen gene therapy combined with stem cell transplantation may provide a
method to direct the differentiation process, enhancing the recovery of specific cellular
functions by stimulating the production of a specific lineage thereby replenishing the
appropriate cell types.  The ability to efficiently transduce unstimulated human stem cells
with the vector of choice must precede experiments directed toward gene therapy
applications.
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Several vehicles and methodologies have emerged as potential gene delivery
systems for therapeutic applications.  Both viral and non-viral vectors have been
employed for stem cell transduction with each having distinct benefits and disadvantages.
For stem cells, issues relevant to the choice of vector include: (i) efficiency of
transduction, (ii) mitotic state of the target cell (quiescent vs. dividing), (iii) maintenance
of transduced DNA (integration vs. episomal), (iv) length of transgene expression
(transient vs. long-term), (v) vector capacity, and (vi) unwanted host immune recognition
of the transduced cells.
Initially, for stem cell transduction experiments, retroviral vectors were utilized
for their ability to integrate a transgene into the host genome.  Early in vivo experiments
using murine hematopoietic stem cells compared ecotropic and amphotropic MMLVs
carrying genes such as adenosine deaminase or glucoceribrocidase(32).  Donor cells were
infected and transplanted into irradiated hosts.  Long-term viral vector presence was seen,
but at very low levels, in the amphotropic compared to the ecotropic vector.  This may be
partly explained by the differences in receptor expression levels in these cells.  The
amphotropic receptor GLVR2 was undetectable by RT-PCR.  Several reports have shown
that infection levels can be increased by the addition of cytokines to the cultures.  This
stimulation may be especially important for viral integration into non-dividing cells.
Initial attempts using the amphotropic MMLV to transduce unstimulated
nonhuman primate and human hematopoietic stem cells have yielded poor transduction
efficiency(32,198).  Emery, et al.(199) reported 9.6% of human CD34+ stem cells were
transduced by MMLV coding for neomycin resistance.  The analysis was made on colony
assays grown under selection.  The transduction method involved culturing the cells in
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Interleukin-3 (IL-3), IL-6 and stem cell factor (SCF) with two doses of vector at MOIs of
up to 100 each.  This could be increased slightly (1.6 fold) by culturing at 33°C.
Cavazzana-Calvo, et al.(197) cultured human CD34+ marrow cells on fibronectin coated
plates in medium supplemented with calf serum, SCF, IL-3, and, FLT-3 Ligand (FL).
MMLV vector carrying the γc cytokine receptor gene (SCID-X1 disease) was added daily
for 3 days at an MOI of 1 each time.  PCR analysis showed 20-40% of cells were
expressing the gene and immunofluorescence showed 36% γc positive.  The cells were
transplanted after day three and 10 months later transgene expressing cells (T and natural
killer-NK) were detected in two patients, and provided correction of the SCID mutation.
Miyoshi et al.(200) compared VSV-G pseudotyped Lenti and MMLV vector transduction
of CD34+ human umbilical cord cells in SCF, IL-3, and IL-6.  The cells were exposed for
5 hours to MOIs of 60 or 300 of each vector.  Five days later transduction levels were
comparable between vectors with 54% and 50% GFP positive at the higher MOI for Lenti
and MMLV respectively.  Samples of each were removed for colony assays to determine
if CFC progenitors are transduced.  The Lentivirus transduced cells were 8-fold higher in
GFP+ colonies than the MMLV infected cells.  This may indicate that MMLV is not
efficient at infecting more primitive progenitor cells.  Dao, et al.(201) and Uchida, et al.(202)
also reported that MMLV vectors are inefficient at transducing CD34+CD38- cells.
Evans, et al.(203) transduced human cord blood cells enriched for the CD34+CD38-
population with VSV-G Lentivirus.  The cells were cultured in SCF, FLT-3 ligand (FL),
IL-3, and IL-6 and two doses of MOI 20 were used.  The average transduction efficiency
was 59% while a comparative experiment with MMLV showed <4% GFP positive cells
by flow cytometry.  The Lentivirus transduced cells maintained this level of transduction
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for at least 13 days in culture.  These and other similar results indicate that Lentivirus is a
more efficient vector than MMLV for the transduction of a variety of stem cell types and
should be very useful as developments continue(204-206).
AAV vectors have recently been explored for the ability to transfer genes into
human stem cells(207-209).  Nathwani, et al.(210) have developed AAV vector stocks
deficient of helper and wild-type virus for gene transfer to human cord blood CD34+ and
CD34+/CD38- cells.  Using high MOIs of 1×106 and stimulating in high dose cytokine
enriched medium for 48 hours, CD34+ cells were 23% positive for GFP.  In a second
experiment, tumor necrosis factor (TNF) was also added to the culture and increased the
transduction to 51%.  Approximately 33% and 60% of the CD38- cells were GFP+ in the
absence or presence of TNF, respectively.  The gene expression, however, was reported
to be transient, indicating that possibly either the virus was episomal or the integrated
vector was silenced.
Efficacy of gene transfer to human blood stem cells was examined using the
nonintegrating Adenoviral vectors.  Watanabe, et al.(2 1 1 )  transduced human BM
mononuclear and CD34+ cells at MOIs of 5, 50, and 500.  The cells were cultured in
IMDM with 10% FBS at 1×106/mL and virus was added.  After 24 hours, the cells were
harvested and assessed for transduction efficiency and colony assays were started with
FACS positive cells.  The CD34+ cells averaged 7%, 12%, and 21% lacZ positive by
fluorescein di-β-D-galactoside (FDG) staining at 5, 50 and 500 MOI respectively.
Approximately 22% of the CD34+/CD38- cells were FDG positive at the high MOI.
Colony assays showed deleterious effects on colony numbers at the high MOI, but the
low and mid MOIs were comparable to the uninfected colony numbers.  Neering, et
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al.(212) transduced human BM, mobilized PB, and UCB CD34+ cells with Ad vectors that
encode either a lacZ or alkaline phosphatase (AP) reporter gene.  The cells were cultured
in medium supplemented with 5% FBS, IL-3, IL-6, and SCF and an MOI of 500 was
added 12-16 hours post plating.  The cells were assayed 2 days later by flow cytometry.
The BM cells were 45%, CB cells were 25%, and MPB were 23% AP positive.
CD34+/CD38- cells were 30% AP positive.  Propidium Iodide (PI) is a viability dye that
stains dead cells red.  Cells at this MOI were on average 7.3% propidium iodide positive
versus 5% in uninfected cells.  Frey, et al.(213) demonstrated 19% GFP+ cells infected with
Ad at an MOI of 50 for PB CD34+ cells 24 hours post infection.  Higher levels of
transduction were achieved when the cells were expanded for 10 days in various cytokine
cocktails before infections.  The level of adenoviral transduction appears to be limited by
the presence of the major coxsackie and adenoviral receptor (CAR) on just 6-15% of
CD34+ cells(214,215).
Little research has been published on the infection of stem cells with HSV-1.
This may be partly due to the fact that HSV does not integrate into the host cell
chromosome, thus limiting its applications for gene therapy in CD34+ cells.  Dilloo, D, et
al.(89) have shown that a disabled infectious single-cycle (DISC) HSV, an attenuated
single replication cycle vector, can infect human bone marrow CD34+ stem cells.  The
cells were cultured in stromal support cultures and exposed to an MOI of 2 for 2 hours
and nearly 100% of the cells were reporter gene positive (LacZ gene driven by Simian
Virus 40 promoter).  This peak number occurred between 24-48 hours post-infection.
Toxicity was low with 70-100% of the cells surviving the transduction.  Long-term
expression in culture was shown by a 27.5% lacZ+ population at day 14, and 1-2% by day
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21.  It is important to note that this virus replicates once but does not seem to cause death,
according to the report, even though similar vectors have been shown to be highly
cytotoxic.
Coffin, et al.(216) have infected human peripheral blood CD34+ cells with a
replication attenuated HSV vector deficient in ICP34.5 and UL43.  The cells were
concentrated to 1×107/mL and infected at an MOI of 10 for 2 hours.  At 24 hpi, FACS
analysis shows CMV-GFP+ cells (10%).  These cells were sorted for green and then
stained for a second reporter gene’s expression (LacZ under a Rouse Sarcoma Virus-RSV
promoter in UL43) with X-Gal (5-Bromo-4-chloro-3-indolyl beta-D-galactopyranoside).
These sorted cells were found to be 100% positive for both genes.  This report showed a
marked decrease in transduction as compared to the Dilloo publication.  Upon
comparison several parameters that may be resulting in these differences include the
tissue the cells are derived from, the viral adsorption step and the culture medium.
Gomez-Navarro, et al.(195) have infected CD34+ human peripheral blood and
monkey bone marrow cells with a non-replicative HSV-TOZ viral vector developed in
the Glorioso lab.  This vector is deficient in 3 immediate early genes, contains the lacZ
reporter gene under control of the ICP0 promoter, and expresses thymidine kinase from
the ICP4 promoter.  The cells were incubated at 1×106/mL in 12 well plates.  HSV-TOZ
was directly added to the cultures at various MOI.  At 12 hpi, FACS analysis for lacZ by
FDG staining shows 99.9% positive cells at an MOI of 3.  The infected cell culture
showed no significant decrease in the number of viable cells at days 2, 4, or 7 post
infection when compared to uninfected cells.  In vivo experiments were performed on
monkeys with healed skin autografts.  Infected cells were transplanted and skin autograft
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biopsies were taken and analyzed 5 days later.  Results have shown infected cell targeting
of the vascular walls by X-Gal staining and by in situ hybridization with both a LacZ
gene probe and an HSV sequence probe.  Mononuclear cells from the peripheral blood
and bone marrow of the monkeys showed FDG positive cells for over 3 weeks.
Ganciclovir was administered daily for 2 weeks to animals starting at 15 days post
infected cell transplantation.  The treatment induced a progressive necrotic process that
was complete 5 days after the treatment ended such that the healed autograft lost blood
supply and detached.
It is important to note that various detection methods were used to analyze the
infected stem cells.  Some reports analyzed the LacZ reporter gene by FDG loading.
FDG is a substrate for β-galactosidase that is cleaved and results in fluorescein.  This is
sensitive and can be detected from <5 to >50,000 enzyme molecules per cell.  A potential
problem is that fluorescein can leak out of these cells and be taken up by other cells,
giving false positives(217).  β-galactosidase is also present in viral preparations from the
production and purification, thus adding an alternate source for the enzyme other than the
infected cells being analyzed.  X-Gal is a stain, similar to FDG, that can be used to
visually determine β-galactosidase expressing cells but can be shady and thus subject to
personal opinion.  Another common reporter system used is GFP, which can be visually
monitored by fluorescence microscopy or flow cytometry.  Cells expressing GFP may not
be detectable at the same low levels that β-galactosidase stained with FDG or X-Gal are,
due to the multiple reactions that may occur per enzyme.  These analytical differences
may result in discrepancies when determining and comparing what percentage of cells,
by reporter gene expression, have been transduced.
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1.4  SUMMARY
The research performed for this thesis involves studies in three interrelated areas of
replication-defective herpes simplex virus type-1 gene therapy vectors: application,
production, and purification.
Hematopoietic stem cells have received much attention recently for the ability to
“home” and differentiate into a variety of tissue, as well as repopulate a body’s blood cell
lineages.  These unique properties make it an interesting tissue to study gene transfer into
for potential tissue-specific therapeutic strategies.  Current viral vectors have shown poor
transduction results and require high levels of stimulating cytokines for achieving these
results.  In this thesis, studies on optimizing gene transfer to human umbilical cord blood
CD34+ cells are described.  The presence and functionality of the herpesviral receptors
were analyzed and new vectors were developed in multiple gene-deleted backbones in
hopes of attaining decreased toxicity and tissue specific expression.
The CD34+ cell transduction studies indicate a potential application for HSV-1
vectors.  It was also learned that large amounts of vector will be required to make this a
realistic treatment strategy.  Therefore I next examined the effect of temperature and
media conditions on vector stability.  Applying these results to production scenarios
demonstrated the ability to increase production levels of the vector through manipulation
of culture conditions.
The FDA establishes guidelines on the amount of non-virion associated DNA and
protein that can be injected into a human patient per dose of therapeutic.  Thus the
production of large amounts of vector for treatment of disease must be accompanied by a
scalable purification system that meets these guidelines.  In this work I studied the use of
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filtration and chromatographic procedures that when combined provide a novel strategy
aimed at concentrating and purifying high levels of produced vector.
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2.0  MATERIALS AND METHODS
2.1  Gene Transfer to Human Umbilical Cord Blood CD34+ Cells
2.1.1  Cell Culture
CD34+ cells from human umbilical cord blood were subjected to positive
selection by magnetic bead column chromatography according to the manufacturer's
protocol (Miltenyi, Auburn, CA).  Briefly, mononuclear cells obtained by Ficoll-Paque
centrifugation are labeled with a hapten conjugated anti-CD34 antibody and purified with
an anti-hapten secondary antibody attached to a magnetic bead.  The recovered cells are
washed and resuspended in BIT9500 (StemCell Technologies, Vancouver, BC) diluted
with Iscove's Modified Dulbecco's Medium (Life Technologies Inc., Gaithersburg, MD)
as directed and supplemented with 50 ng/mL stem cell factor (SCF) and 10 ng/mL
thrombopoietin (StemCell Technologies).  A sample of both the unlabeled mononuclear
and CD34+ enriched cells are then removed and labeled with a CD34 antibody
recognizing a different epitope and stem cell purification assessed by flow cytometry.
Vero cells obtained from ATCC (CCL81) are cultured in Minimum Essential
Medium (Life Technologies Inc.) supplemented with 10% fetal bovine serum (FBS), 2
mM L-glutamine, and 100 U/mL Penicillin and Streptomycin (Life Technologies Inc.).
The ICP4/ICP27 IE gene complementing cell line, 7b(75,218), is cultured identical to Vero
cells.  CHO cells expressing Herpesvirus entry mediator receptors A or C (HveA or
HveC) designated as M1A or M3A(100) respectively, were a gift from Dr. Gary Cohen and
Dr. Roselyn Eisenberg (University of Pennsylvania).  CHO lines are cultured in F-12K
medium supplemented with 10% FBS, 100 U/mL Penicillin and Streptomycin, 250
µg/mL G418, and 150 µg/mL Puromycin (Life Technologies Inc.).
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2.1.2  Virus Vector Construction
The construction of the multiple IE gene deletion mutant QOZHG has been
described previously(219).  This viral recombinant has deletions of the essential IE genes
ICP27 and ICP4.  The TAATGARAT sequences within the ICP22 and ICP47 promoters
have been mutated(77,138) so they are no longer recognized and activated by VP16, and
hence are confined to expression as early, or β genes in complementing cell lines.  The
reporter gene cassette consisting of the human cytomegalovirus IE promoter driving
enhanced green fluorescence protein (HCMV IEp-GFP) is present in the ICP27 locus.
The virion host shutoff gene UL41 is disrupted by the insertion of an HSV-1 ICP0 IE
promoter-lacZ expression cassette.  This vector was created by a genetic cross of the
vector TOZ.1 (ICP4-, ICP27-, ICP22-, UL24
-::ICP4 IEp-thymidine kinase, UL41
-::ICP0
IEp-lacZ)(218) and d106 (ICP4-, ICP27-::HCMV IEp-GFP, βICP22, βICP47)(77,138) and
was propagated on complementing 7b cells.  Vector stocks were purified using OptiPrep
(Life Technologies  Inc., Cat. No. 103-0061) gradients and titered on 7b cells.
TOZ.1, a triple IE gene deletion mutant virus with the deletion of three IE genes
(ICP4, ICP27, and ICP22), contains the lacZ gene inserted under control of the ICP0
promoter(218) in the UL41 locus. In addition, the normal early gene promoter for
thymidine kinase (UL23) has been altered by the substitution of the ICP4 IE gene
promoter which also affects the downstream reading frame encoding UL24.  TOZHG is
identical to TOZ.1 except that it also carries a reporter gene cassette consisting of the
human cytomegalovirus IE promoter driving enhanced green fluorescence protein
(HCMV IEp-GFP) within the ICP27 locus.  The GFP transgene was obtained from the
pEGFP-N1 plasmid (Clontech).  Vectors expressing a transgene from the HSV latency
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active promoter (LAP2), an endothelial specific promoter (vWF), or a combination of
these have been similarly engineered.  Breifly, recombination plasmids were developed
that contain the desired promoter with GFP flanked at both ends by ICP27 gene
sequences.  Recombinant vectors are developed by first infecting 7b cells at MOI=3 with
the background vector (TOZ.1).  The cells are then transfected with the desired
recombination plasmid.  The infection/transfection culture is harvested when cytopathic
effects are visually present.  The harvested vector is screened by infections of limiting
dilutions and visually monitoring developing plaques for GFP expression.
The human erythropoietin expressing vector, DHEPO, has deletions of the
essential IE genes ICP27 and ICP4.  The expression cassette consisting of the human
cytomegalovirus IE promoter driving human erythropoietin (HCMV IEp-EPO) was
recombined into the UL41 locus of the vecotr DHZ.5 that contains an HCMV IEp-lacZ
reporter cassette in UL41.  LacZ
- recombinants were identified, subjected to three rounds
of limiting dilution and the presence of the EPO expression cassette in the UL41 locus
confirmed by Southern blot analysis.
2.1.3  Flow Cytometry Analysis of GFP
QOZHG HSV-1 vector transduced cells were washed twice and resuspended at
0.25x106/mL in 1% FBS and 1% paraformaldehyde in PBS.  Minimally 1×105 total cells
per sample were added to 5 mL round bottom polystyrene tubes (Falcon/Becton-
Dickinson, San Diego, CA).  The cells were analyzed by flow cytometry (FACSCalibur
or FACSTAR, Becton-Dickinson) using a mock sample as the forward and side scatter
control to set cell population gating and as the autofluorescence control to set
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fluorescence gating boundaries.  Cell data was typically collected for 10,000 gated events
per sample.
2.1.4  Flow Cytometry Analysis of HveA and HveC
CHO-HveA (M1A), CHO-HveC (M3A), or CD34+ cells were concentrated to
1×106/mL in 1% FBS/1×PBS.  Aliquots of 2x105 cells were incubated with either anti-
HveA (1:300 dilution in PBS/1%FBS), anti-HveC (5 µg/mL) or both antibodies for 30
minutes on ice.  Both anti-HveA (R140, polyclonal)(97) and anti-HveC (CK41,
monoclonal)(100) were gifts of Drs. Cohen and Eisenberg (U. of Penn.).  For CD34+ cell
analysis, CK41 was biotinylated using EZ-Link Sulfo-NHS-LC-Biotin (Pierce, Rockford,
IL).  Cells were diluted, washed twice, and resuspended at 1×106/mL and incubated with
either FITC-conjugated anti-rabbit secondary antibody (1:150, Sigma, St. Louis, MO),
PE-conjugated anti-mouse secondary antibody (1:150, Sigma), or strepavidin-PE
conjugated secondary antibody (Sigma) for CD34+ cells, or both secondary antibodies for
30 minutes on ice.  Cells were again washed twice, and resuspended at 0.25x106/mL in
1% paraformaldehyde, 1% FBS in PBS.  The cells were analyzed by flow cytometry as
described above for GFP.  For analysis of GFP and either receptor, anti-HveA was
labeled with Cy3-conjugated anti-rabbit secondary antibody and anti-HveC was labeled
with either strepavidin-PE (Sigma) or strepavidin-APC conjugated secondary (Sigma) as
indicated.  This analysis was performed for two separate cell harvests.
2.1.5  Immunohistochemistry for ICP0
CD34+ cells (1×106/mL) were either mock-infected or infected with vector at an
MOI of 30 immediately after purification and directly incubated in a 12-well tissue
culture plate at 37°C/5% CO2.  Sixteen hours after vector addition the cells were removed
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from culture, washed, and resuspended in PBS containing 1% FBS.  1×105 cells were
removed from each sample, fixed in 1% paraformaldehyde, and analyzed for GFP
expression by flow cytometry.  Cytospins of 1×105 cells per slide (superfrost/plus; Fisher,
Pittsburgh, PA) were prepared by centrifugation at 450 rpm for 5 minutes at room
temperature, fixed with 100% cold methanol for 2 minutes, and allowed to air dry.  Slides
were blocked with 10% horse serum in PBS for 1 hour at room temperature, incubated
with primary ICP0 monoclonal antibody (1:2000 dilution: Virusys; East Coast Biologics,
Inc., North Berwick, ME) at 4°C overnight.  The cells were washed twice in PBS/1%
FBS and incubated with PE-conjugated anti-mouse secondary antibody (1:500, Sigma)
for 2 hours at room temperature in the dark.  The slides were then washed twice with
PBS, overlayed with Gel/mount (Biomedia, Foster City, CA), and a coverslip applied.
Slides were maintained at 4°C in the dark and images collected by fluorescence
microscopy using a Xillix digital camera attached to a personal computer-based image
analysis system (MCID, St. Catharines, Ontario, Canada).
2.1.6  Immunohistochemistry for PML
Uninfected CD34+ cells were prepared as described for ICP0
immunohistochemistry except that cells were stained with monoclonal anti-PML
antibody (0.25 µg/mL or 0.8 µg/mL dilution, Santa Cruz Biotechnology, Santa Cruz, CA)
and FITC-conjugated anti-mouse secondary (1:500, Sigma).
2.1.7  Immunohistochemistry for HveA and HveC
Cells were prepared as described in the Flow Cytometry Analysis methods except
Cy3-conjugated anti-rabbit secondary antibody was used in place of FITC-conjugated
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secondary antibody for HveA analysis.  Cytospins were prepared as above except cells
were fixed with 1% paraformaldehyde prior to cytospin.
2.1.8  Dextran Sulfate Analysis
CD34+ cells were harvested, resuspended at 1×106/mL, and plated in a 96-well
plate at 1×105 per well.  Various amounts of dextran sulfate (Amersham Pharmacia
Biotech, Piscataway, NJ) were mixed thoroughly with the cells and incubated at room
temperature for 10 minutes.  QOZHG vector was then added (MOI=5 or 10), mixed
thoroughly, and incubated at 37°C.  Sixteen hours post infection the cultures were
washed twice with medium and resuspended at 0.25x106/mL in 1% paraformaldehyde
and 1% FBS in PBS and GFP expression analyzed by flow cytometry.  Transduction with
MOI 5 or 10 were performed on separate cell harvests.
2.1.9  Neutralization Assay
CHO-HveA (M1A), CHO-HveC (M3A), or CD34+ cells (1×106/mL) in their
respective mediums and anti-HveA, anti-HveC, or both antibodies were added at the
indicated concentrations and incubated at 4°C for 1 hour.  QOZHG vector was added at
the indicated MOI and mixed.  CHO-HveA and CHO-HveC cells were rocked for 1 hour
at 37°C, washed twice with medium, plated, and incubated in the appropriate medium at
37°C.  CD34+ cells were plated without washing, and incubated at 37°C.  All cultures
were harvested 16 hours post viral addition, washed twice, resuspended at 0.25x106/mL
in 1% paraformaldehyde and 1% FBS in PBS, and analyzed by flow cytometry for GFP
expression.  The experiment was performed in duplicate using cells obtained from one
harvest.
38
2.1.10  Erythropoietin ELISA
Isolated CD34+ cells (1×106/mL) were either mock infected or infected at MOI=3,
10, or 30 with DHEPO by the optimized transduction method determined for QOZHG.
The cells were cultured in BIT9500 with SCF and TPO.  Samples of culture supernatant
were removed daily and analyzed for EPO production by ELISA, as per manufacturer's
protocol (R&D Systems, Inc., Minneapolis, MN).  The experiment was performed on one
cell harvest and samples were analyzed in duplicate.
2.2  Vector Production
2.2.1  Cell and Virus
The replication defective mutant vector TOZ.1 is deleted for the IE genes ICP4,
ICP27 and ICP22, as well as the virion host shut-off (vhs) protein (UL41) and UL24
(218).
In addition it contains a reporter gene cassette consisting of the lacZ gene under the
control of the ICP0 promoter inserted within the UL41 locus.  The 7b cell line is a Vero
cell derivative designed to express the essential IE genes ICP4 and ICP27 upon
infection(75,218).  The 7b cells were maintained in 150 cm2 vented cap flasks (Becton
Dickinson, MD) with 25 mL of Minimum Essential Medium (MEM) w/ Earle’s salts,
1500 mg/ml sodium bicarbonate, 2 mM L-glutamine, 100 U/mL Penicillin, 100 µg/mL
Streptomycin, and 10% Fetal Bovine Serum (Life Technologies, Gaithersburg, MD).
MEM, with supplements, was used for all experiments except where noted.  The cells
were maintained in a 37°C incubator at 5% CO2 with a humidifying water pan.  The cells
were subcultured by seeding at 0.3×105 cells/cm2 and removed by trypsinization when
reaching about 1.2×105 cells/cm2 (100% confluency).
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2.2.2  Cell Growth Experiment
Cells grown at 37°C were subcultured into 25 cm2 flasks (Becton Dickinson, San
Diego, CA) with 2.25×105 cells in 3.6 mL fresh serum medium and incubated at 37°C or
33°C.  Duplicate flasks were harvested for each temperature and time, and viable cell
counts performed using Trypan Blue (Sigma, St. Louis, MO) non-viable cell stain.
2.2.3  Virus Titer
Viral titers were determined by performing standard viral plaque assays.  Serial
dilutions of virus samples were incubated with 1×106/mL freshly trypsinized 7b cells in
1.5 mL safe-lock eppendorf tubes on a Nutator rocker (Becton Dickinson) at 37°C for 1
hour.  Infected cells were plated on 12-well plates (Becton Dickinson) at 3.2×105
cells/well (80% confluency) in a final volume of 800 µL.  After cell adhesion (12 hours),
the medium was removed and replaced with a solution of 0.5% methyl-cellulose
(Aldrich, Milwaukee, WI) in supplemented MEM.  Cultures were stained after 4 days
with 1% crystal violet (Sigma) in MeOH/water (50%/50%) and the number of plaques
counted.  All assays were performed in duplicate and results are presented either as the
number of plaque forming units per volume (PFU/mL) or per cell (PFU/cell).  Titers less
than 103 were not recorded.
2.2.4  Synchronous Infections
Freshly trypsinized 7b cells grown at 37°C were suspended at 1×106/mL in fresh
serum medium in 1.5 mL eppendorf tubes and stock vector was added corresponding to 5
PFU per cell (high MOI) to ensure all cells are simultaneously infected.  Titers of viral
stocks were determined by plaque assays of aliquots of the stocks prior to and again
concurrently with initiation of the experiment.  The infection solutions were rocked for 1
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hour, centrifuged (514×g), the supernatant removed, and the cells resuspended in fresh
serum medium.  The cells were then plated in duplicate in 96-well plates (Becton-
Dickinson) at 3.3×104 cells/well in a total volume of 100 µL and incubated at 37ºC or
33ºC.  Wells were harvested at various times post infection by first removing the
supernatant then harvesting the cells by adding 100 µL of fresh serum-free medium and
scraping the well with a pipette tip.  The samples were stored at –70ºC and titered
simultaneously at the end of the sampling period.
2.2.5  Production Infections
Infections were performed similar to synchronous infections.  Viral stock was
added to cells of passage 30, 45, or 80, corresponding to 0.05 PFU per cell (low MOI)
and infections were plated into 6-well plates (Becton Dickinson) at 8×105 cells in a total
of 2 mL fresh serum medium per well and incubated at 37ºC or 33ºC immediately or
shifted to 33ºC 24 hours post plating.  Samples of 30-40 µL of supernatant were removed
at various times following infection and the medium replaced with fresh serum medium
to maintain a constant volume.  The experiments were performed on two cell populations
that were separated after drug selection.
2.2.6  Virus Decay Experiments in Media with or without Serum
A stock of virus was prepared by harvesting viral supernatant from 10-150 cm2
tissue culture plate infections and centrifuging (514×g) to remove cell debris.
Supernatant was then centrifuged (40,000×g) to pellet the virus, which was subsequently
resuspended in 1 mL of medium without serum, aliquotted, and stored at -70°C.  Stocks
were typically 1-2×108 pfu/mL.  An aliquot was thawed and diluted with the fresh serum-
containing medium or medium without serum to approximately 1-2×106 PFU/mL to
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mimic the viral concentration in the supernatant of infected cells.  Duplicate 6-well plates
of this virus solution were incubated at 37°C and 33°C in a total volume of 2 mL per
well.  Samples were removed at time points, frozen, and titered as above.  The numbers
of infectious viral particles were determined over time, plotted, and an exponential trend-
line was determined by Excel.
2.2.7  Virus Decay Experiments in Culture Conditioned Medium
To obtain conditioned medium, infections were performed in 6-well plates and the
culture medium was removed (60 hours post-infection) and centrifuged (514×g) to
remove cellular debris while retaining the released virus in the medium.  This supernatant
was re-plated to empty plates (no cells) and incubated at 37°C or 33°C to mimic released
virus in the conditioned medium.  The numbers of infectious viral particles were
determined over time, plotted, and an exponential trend-line was determined by Excel.
2.2.8  Glucose and Lactate Assays
Samples were obtained from duplicate infected cell cultures (performed as
described previously in 'Production Infections' section) conducted at 37ºC and 33ºC and
stored  at -70°C  until analyzed with enzymatic assay kits (Sigma) to  measure glucose
concentration (Cat. No. 16-50) and lactate concentration (Cat. No. 735-10).
2.3  Vector Purification
2.3.1  Vector Centrifugation
Low Speed: Vector infection cultures were harvested and centrifuged (Beckman,
Model GPC, Rotor No. GH-3.7) at 1000×g for 10 minutes at 4°C.  Clarified supernatants
were removed from pelleted debris and processed as indicated.  High Speed: Vector
supernatant was centrifuged at either 13,000×g, 27,000×g, or 48,000×g for 10, 20, or 30
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minutes at 4°C (Beckman, Model No. J2-21M, Rotor No. JA-20).  Supernatants were
removed and the pellets were resuspended to a 50× concentration in serum-free medium.
Centrifugation experiments were performed in duplicate and titers were performed on
both supernatant and pellet to analyse vector presence.
2.3.2  Dead-End Filtration of Vector
Syringe Filtration: Centrifuge-clarified virus supernatant (1 mL) was filtered
separately or serially through a 1.2 µm,  0.8 µm (Schleicher and Schuell, Cat. Nos.
10465206 and 10465204 respectively), 0.65 µm (Osmonics, Cat. No. SO6SP02500), 0.45
µm, or 0.22 µm (Millipore, Cat. Nos. SCHA0250S and SLGVR25LS respectively)
syringe filter using luer lock 3 mL sterile syringes.  The experiments were performed in
duplicate and flow-through vector samples were titered to analyze vector recovery.
Centrifugal Filtration: Infection culture harvests were clarified by centrifugation and
either unfiltered (10 mL or 20 mL) or filtered through a 1.2 µm or 0.65 µm syringe filter
(10 mL) and loaded onto 300,000 molecular weight cut-off, 20 mL capacity Centricon
centrifugal filters (Millipore, Cat. No. SE3P001L99).  The vector was centrifuged at
1000×g and 4°C.  The process was stopped periodically to monitor retained volume.
When desired concentration was reached, the retentate was recovered according to
manufacturers instructions.  Experiments were performed in duplicate and titers were
performed on vector before centrifugal filtration and on recovered vector.
2.3.3  Electron Microscopy
Transmission electron microscopy analysis was performed on a sample obtained
from the vector production harvest.  Harvest supernatant with cell debris was pelleted by
centrifugation at 20,000×g for one hour.  The pellet was fixed with glutaraldehyde,
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stained with osmium tetroxide and dehydrated by a series of increasing concentration
ethanol washes.  The pellet is then coated in Epon, embedded, and cured.  Slices of 90
nm were collected on copper grids and coated with methanol and uranyl acetate, washed
and treated with lead citrate.  After drying, the samples were viewed by electron
microscopy and photographed at various magnifications.
2.3.4  Heparin Chromatography
Vector prepared by centrifugation was purified using a 1 mL heparin
chromatography column (Amersham Pharmacia Biotech, Cat. No. 17-0406-01).  Heparin
columns are prepacked with 6% agarose beads of 34 µm diameter.  The beads are loaded
with 10 mg heparin per mL of gel.  The bead pores have a 4×106 molecular weight
exclusion limit.
Centrifuged vector was resuspended in 1× phosphate buffered saline (PBS) and
loaded at 0.7 mL/minute using a Pharmacia LKB Pump P-1.  The column was washed
with a series of 5 column volumes of PBS containing 0.133 M, 0.5 M, 1.5 M, and 3.0 M
NaCl.  Elutes were analyzed for vector presence by titration and total protein by Bio-Rad
colorimetric assay (Bio-Rad, Hercules, CA, Cat. No. 500-0006).
Vector purified by tangential-flow filtration was purified using 5 mL heparin
chromatography columns (Amersham, Cat. No. 17-0407-01).  Vector was loaded at 1.4
mL/minute and washed with 7 column volumes of PBS containing 0.133 M, 0.25 M, 0.75
M, and 1.5 M NaCl.  Each elute was collected as two separate 3.5 column volume
fractions.  Elutes were analyzed for vector presence by titration, total protein by Bio-Rad
Protein Assay, and total double-stranded DNA by PicoGreen (Molecular Probes Inc.,
Eugene, OR).
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2.3.5  Tangential-Flow Filtration
The filters and system used in this work were provided by or purchased from A/G
Technology, Inc (Needham, MA).  The three filters used are 0.8 µm (Cat. No. CFP-8-D-
4MA), 0.65 µm (Cat. No. CFP-6-D-4MA), and 0.1 µm (Cat. No. CFP-1-D-4MA)
nominal pore size.  The surface areas of the filter cartridges were each approximately
0.046 m2 and were packed with 75 hollow-fiber tubes of 0.75 mm internal diameter each.
The pump and stand system used is the Quixstand (Cat. No. QSM-03S) with a
Watson/Marlow 313S 400 rpm pump.  Initial running parameters were determined by
conferring with the manufacturer.  A feed flow of near maximal pump capacity was used
in order to minimize gel layer formation.  This corresponded to a flow rate of 1 L/min or
a shear rate of 5,300 sec-1 based on clean water flux studies.  The permeate collection
flow rates were maintained at 25-30 mL/min as a compromise to prevent pore plugging
due to high flux rates yet still provide a reasonable process time, considering process
volumes of 1-2 liters.  This flow rate was achieved by the use of a permeate control pump
(Cole-Parmer, Cat. No. 7553-30) for the 0.8, 0.65, and 0.1 µm filters.
To analyze the large-pore filter systems, the 0.8 and 0.65 µm filter systems were
each loaded with 1 liter of total vector infection harvest.  The system was run as
described until the retained solution was at the system hold-up volume of 100 mL.
Permeate was collected and analyzed for clarified vector.  High recovery of vector (up to
90%) in the permeate was achieved by washing the cell debris with PBS, which increased
the total permeate volume to 1.5 L.  The 0.1 µm filter systems were run using the
parameters described and additionally washing the retained vector with PBS to perform a
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buffer exchange prior to chromatography.  Retentate was harvested when the volume was
reduced to approximately 200 mL.  Permeate was also collected and analyzed for vector
passage.
46
3.0  GENE TRANSFER TO HUMAN UMBILICAL
CORD BLOOD CD34+ CELLS
3.1  Introduction
The CD34+ population of cells derived from bone marrow, cord blood or
peripheral blood contain a small population of stem cells capable of reconstituting the
hematopoietic system in bone marrow ablated animals and humans.  Evidence is
accumulating that a similar stem cell population can differentiate into a variety of tissue
types suggesting their broad utility for tissue regeneration.  Alternative hematopoietic
stem cell populations have been used to repopulate damaged liver(220,221) and
muscle(149,153,222).  Published work reported the use of an HSV recombinant vector to
demonstrate homing of infected CD34+ monkey bone marrow cells to sites of
angiogenesis in skin-grafted monkeys(195).  This work indicated that recombinant herpes
simplex virus type 1 (HSV-1) vectors are capable of transduction of stimulated CD34+
cells derived from the bone marrow of primates and mobilized peripheral blood from
humans.  
HSV was shown to provide a useful vector system for gene transfer applications
where modified stem cells may be therapeutic, however, neither the receptors used for
virus entry into hematopoietic stem cells nor the susceptibility of unstimulated human
cells to HSV-mediated gene transfer have been determined.  In addition, the optimal MOI
and minimal time of infection have not been established.  In this study, I evaluated the
ability of a replication defective HSV vector for marker gene transfer to unstimulated
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human CD34+ stem cells derived from human umbilical cord blood.  One or both of the
HSV receptors HveA and HveC were detected on 95% of CD34+ stem cells and infection
was inhibited by combined receptor specific antibodies.  The virus receptor interactions
were novel in as much as virus-exposed cells resulted in the loss of cell surface HveC, an
effect not observed for HveA.  Under optimized conditions, we observed transduction
efficiencies of 55%-75% with minimal adsorption times of 10 hours, confirming that HSV
vectors may provide an important tool for advancing stem cell biology and the use of
unstimulated CD34+ stem cells for regenerative therapies.  Specifically, I have
demonstrated this by employing a replication defective HSV vector that was capable of
secreting the therapeutic product erythropoietin.
3.2  Results
CD34-expressing cells were selected by antibody-magnetic bead column
chromatography on mononuclear cells isolated from human umbilical cord blood obtained
at cesarean-section births.  These stem cell enriched populations, typically greater than
90% CD34+ (Figures 1A & B), were used for all subsequent experiments.
3.2.1  Conditions for HSV Infection of Unstimulated CD34+ Cells
Experiments were performed to establish optimal conditions for infection of
unstimulated CD34+ cells in culture using a replication-defective (ICP4–, ICP27–)
recombinant HSV vector, QOZHG(219), which carries a GFP reporter expression cassette
in the ICP27 locus and a lacZ cassette in the UL41/vhs locus gene (Figure 1C).  ICP0 is
the only unaltered viral IE gene expressed from QOZHG.
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Figure 1.  Flow Cytometry analysis of human umbilical cord blood cells and schematic of
the HSV-1 vector QOZHG.
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Initial transduction experiments performed on the CD34+ cells employed standard
methods used to transduce Vero cells, which are highly susceptible to HSV-1.  The
standard method of infection is to concentrate the cells at 1×106/mL in a tube, add virus,
rock for 1 hour at 37ºC, wash, and then plate the cells.  This protocol resulted in 96% of
Vero cells transduced at MOI=5.  In contrast, relatively low transduction levels (9%) of
CD34+ cells were observed, even at MOI=50, using flow cytometry analysis of GFP+
cells (Figures 2A & B).
Systematic variation of cell densities, viral adsorption times, and vector doses
(MOIs) revealed maximum transduction efficiencies in the range of 60-75% at an MOI of
30.  Extension of virus adsorption times had marked positive effects on transduction at
optimum cell densities of 1-5×106/mL (Figure 3A).  As expected, transduction efficiencies
increased with increased MOIs, but the differences faded at the highest MOIs (Figure
3B).  Analysis of the flow cytometry histogram for an infection at MOI=30 and 16 hour
adsorption shows a range of GFP expression including a population of highly fluorescent
cells at the far right of the plot (Figure 3C).  From these results, infection conditions were
standardized to virus incubation with 1×106 cells/mL in tissue culture wells at an MOI of
10-30 for 16-18 h after pipettor mixing and before virus removal by washing and
subsequent plating or analysis.  Routine transduction efficiencies under these conditions
were 35-45% (MOI=10) and 60-70% (MOI=30).  
The QOZHG vector is replication defective, and the only genes expressed are the
two transgenes (GFP and lacZ) and ICP0, the sole IE gene product remaining.  ICP0
protein has been shown to accumulate in the nucleus and co-localize with nuclear domains
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Figure 2.  Flow cytometry analysis of QOZHG transduced Vero and CD34+ cells.
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Figure 3.  Transduction of CD34+ cells with QOZHG vector.
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(ND10s)(223-225) also called PML (promyelocitic leukemia) bodies.  By
immunohistochemistry, PML bodies were visible in approximately 95% uninfected
CD34+ cells (Figure 4A) while nuclear ICP0 accumulation (Figure 4B) was seen in >50%
of infected (MOI 30) cells.  Various intensities of ICP0 were observed suggesting that
some cells may express low levels of ICP0 beyond the detection limits of
immunofluorescence.
Based on these results, two issues were further explored.  First, we examined
whether the extended adsorption times required for maximal transduction was indicative
of a deficiency in glycosaminoglycans (GAGs) on the surface of CD34+ cells limiting the
rate of initial virus attachment.  Second, we examined the distribution of the HSV gD
receptors HveA and HveC on CD34+ cell populations as a possible explanation for the
incomplete transduction of these populations observed even at very high MOI (Figure
3B).  
3.2.2  Involvement of Cell Surface GAGs
Dextran sulfate promotes HSV infection of cells such as sog9 that are deficient for
GAGs, the receptors for initial HSV attachment via gB and gC(226,227).  In contrast,
dextran sulfate inhibits infection of GAG-positive cells.  Infections of unstimulated
CD34+ stem cells were carried out in the presence of increasing amounts of dextran sulfate
and transduction efficiencies determined by flow cytometry for GFP expression.
Inhibition of infection was observed at dextran sulfate concentrations of 0.1 µg/ml or
higher with no effect at 0.03 µg/ml (Figures 5A & B).  This result indirectly indicates that
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Figure 4.  Immunohistochemical analysis of CD34+ cells for (A) PML and (B) ICP0.
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Figure 5.  Effect of dextran sulfate on transduction of CD34+ cells.
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CD34+ cells carry GAGs on their surface which contribute to HSV infection, suggesting
that GAG deficiency was not the cause of the slow kinetics of CD34+ cell infection.
3.2.3  Detection of gD Receptors on Unstimulated CD34+ Cells
Flow cytometry analysis was used to determine the presence of the HSV gD
receptors HveA and HveC on two CD34+ stem cell populations isolated from several
umbilical cords.  In the absence of stimulation, HveA and HveC were detected on 75%
and 85%, respectively, of the cells in one CD34+ cell preparation (Figure 6A).  Dual-label
analysis revealed four distinct subpopulations with HveA (6%), HveC (21%), both
receptors (68%), or neither (5%) present on the cell surface.  Analysis of the second cord
revealed similar subpopulations (Figure 6B), although the percentages were somewhat
different (HveA, 30%; HveC, 7%; both, 57%; neither, 6%).  Immunofluorescent analysis
confirmed the surface expression of HveA and HveC in CD34+ cell populations in
comparison with control CHO cell lines expressing either receptor alone (Figure 7).  Since
more cells carried one or both receptors (94-95%) than could be infected under optimal
conditions at high MOI (70-80%, Figure 2B), the question arose whether both receptors
were functional and whether different receptor-positive subpopulations are susceptible to
infection.
3.2.4  Functionality of gD Receptors on CD34+ Cells
The functional activities of the gD receptors HveA and HveC on CD34+ stem cell
populations were evaluated by virus neutralization assays using antibodies to the
individual receptors.  Antibody specificities and effective blocking dosages were
determined on CHO cell lines expressing HveA (CHO-HveA cells) or HveC (CHO-HveC
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Figure 6.  Dual-label flow cytometry analysis of HveA and HveC on CD34+ cells.
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Figure 7.  Immunohistochemical analysis of HveA on CHO-HveA and CD34+ cells, and
HveC on CHO-HveC CD34+ cells.
Figure 8.  Functional analysis of HSV-1 receptors HveA and HveC on CD34+ Cells.
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cells) from transduced genes (data not shown); untransduced CHO cells are refractory to
HSV infection. Incubation of CD34+ cells with antibodies to HveA for 1 h prior to
infection with QOZHG had a small effect on transduction efficiency (20% reduction)
while pre-incubation with anti-HveC antibodies showed no significant effect (Figure 8).
However, pre-incubation with both antibodies reduced the number of GFP positive cells
by 55%, indicating that either receptor can be utilized for HSV-1 infection of stem cells.
Consistent with this interpretation, the reductions accomplished by the antibodies
separately and together correlated reasonably well with the representations of the
different receptor-bearing subpopulations in the second of the CD34+ cultures studied
above by dual-label flow cytometry (Figure 6B).  Alternatively, it is possible that other
gD receptors were involved in addition or instead of Hve A and HveC, such as 3-OST
modified heparan sulfate(104).
To strengthen the evidence that both HveA and HveC on the surface of CD34+
cells could support infection, dual-label flow cytometry was performed for GFP
expression and each receptor separately after infection.  The results showed that 50% of
the cells in one culture were positive for HveA and GFP while 15% were HveA-positive
but negative for GFP (Figure 9A).  Remarkably, only 6% of the cells in this experiment
were positive for HveC, which compares with a range of 68-85% HveC-positive cells
detected in uninfected cultures (see Figure 6).  To confirm this observation, the HveC
portion of the experiment was repeated using a lower MOI (MOI=10) and a different
fluorochrome for HveC detection, allophycocyanin (APC) which is not affected by GFP
expression, unlike PE.  In this repeat experiment, 84% of the cells in a mock-infected
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Figure 9.  HveA and HveC receptor analysis on infected CD34+ cells.
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population were positive for HveC, but only 4% in a virus-infected culture (Figure 9B).
This dramatic reduction suggests that the receptor was either internalized or down
regulated by virus binding.  Although the numbers indicate that 80% of the cells changed
from HveC+ to HveC– in the presence of virus, GFP expression as evidence of
transduction was observed in only 40% of the cells.  Different interpretations of this
result will be considered in the Discussion.
3.2.5  Erythropoietin Gene Transfer to CD34+ Cells
The glycoprotein erythropoietin (EPO) is the primary cytokine involved in
regulating red blood cell production.  Patients suffering from low levels of EPO are
currently treated by injection of recombinant human EPO (rhEPO) on a daily basis to
balance their red blood cell production.  The level of purity and amounts of recombinant
human protein required has led to the employment of alternative strategies.  An alternate
treatment for this disorder would involve transducing the EPO gene to cells that would
reside in the marrow and continually express the cytokine at relevant levels, thus
replacing the continual need for rhEPO injections.  A subfraction of CD34+ cells may
return to the marrow upon reimplantation and reside there long-term, thus making these
cells a potential target for gene delivery.  In order to test this hypothesis in culture,
isolated CD34+ cells were either mock transduced or transduced with a replication
defective HSV vector containing the HCMV:EPO expression cassette, DHEPO, at
MOI=3, 10, or 30.  Samples of supernatant were removed daily for 7 days and analyzed
by ELISA (Figure 10).  Although EPO was detectable at both MOI=3 (16-38 mIU/mL)
and 10 (56-112 mIU/mL), maximal levels (130-630 mIU/mL) were achieved at the higher
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Figure 10.  Analysis of rhEPO production from CD34+ cells transduced with HSV-1
vector DHEPO at various MOI.
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MOI (30).  Together, these results demonstrate expression of a therapeutic gene product
from HSV vector transduced CD34+ stem cells and that biologically relevant levels of that
product were secreted into the culture medium.
3.2.6  Analysis of CD34+ Cells in Culture Post Infection
Since reasonable levels of transduction have been attained with the QOZHG
vector in the minimal medium, the next goal was to analyze infected and uninfected cells
for up to 1 week in culture.  This involved examining infected cell toxicity, GFP
expression, and characterization of continued surface marker presence or loss thereof such
as CD34.  The day one infected cell analysis showed high levels of transduction with
HSV-1.  Significant toxicity was observed in the high MOI of 30 between 16-40 hpi.
This is seen by flow cytometry analyses and viable cell number counts, which are
summarized in Figure 11 A, B, and C.  Visually after ~24 hours the highly fluorescent
cells were shrunken and pignotic in comparison to the lower and non-fluorescent cells.
The flow cytometry results confirm that virtually no highly fluorescent cells remain on
day 2.  The surface marker CD34 remained on mock cells at high level for 3 days, whereas
the infected cells were dramatically reduced after day 2 (Figure 11 D).
In the next experiment, FACS was performed on infected and uninfected cells at
16 hpi.  The infected cells were sorted and collected by three categories: negative, mid-,
and high fluorescence (Figure 12).  They were each plated into separate wells and visually
monitored.  The results showed virtually all high-level GFP+ cells were dead in 1-3 days
post sorting.  The mid-level GFP cells showed 30-40% death over 1 to 2 days and were
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Figure 11.  Analysis of QOZHG transduced CD34+ cells for one week in culture.
Figure 12.  FACS analyzed regions of QOZHG infected CD34+ cells.
0
20
40
60
80
MOI 30
DAY 1
DAY 2
DAY 3
DAY 7%
 G
FP
+
MOCK MOI 30
1x107
1x106
1x105
V
ia
bl
e C
el
ls
20
40
60
80
100
MOCK MOI 30
DAY 1
DAY 2
DAY 3
DAY 7
1x104
1x105
1x106
MOI 30
DAY 1
DAY 2
DAY 3
DAY 7
DAY 1
DAY 2
DAY 3
DAY 7 %
 C
D
34
+
NEGATIVE
LOW
HIGH
GFP FLUORESCENCE
MOCK
TRANSDUCED
C
D
34
+
 
C
EL
L 
N
U
M
BE
R
G
F
P
+
 C
E
L
L
S
64
not visually fluorescent after this time.  After 2 days, cell growth became dominant in this
culture, with the remaining cells surviving.  The negative population showed high
proliferation and no GFP expression from time of plating.  It may be important to note
that for the in vivo animal models these cells would be infected and infused into the
animal.  Based on adsorption experiments, that time frame would be less than 16 hours
post infection.  Cell survival upon implantation may dramatically increase due to the
body being the natural environment, providing trophic factors to counter any cytotoxic
effects.
The probable cause of in vitro toxicity is that the expressed levels of ICP0 are
very toxic to the cells (Figure 4).  In order to examine this further, a vector, d109 of Dr.
Neil DeLuca’s, is deficient in the ICP0 gene, does possess UL41, and does not express
LacZ, but otherwise is identical to QOZHG.  CD34+ stem cells were transduced with
either d109 or QOZHG and monitored visually.  The d109 infected cells showed no GFP
expression but also no toxicity even at very high MOIs of 100-1000 for at least 3 days
(data not shown).  From this observation, it may be inferred that ICP0 protein has an
effect on HCMV promoter activity in the HSV background and also can have a toxic
effect on infected cells.
The possibility of ICP22 expression in infected cells was explored in addition to
ICP0.  The expression of ICP22 can result in several effects on other genes present in the
virus.  Northern blot analyses performed in the Glorioso lab demonstrate that ICP22 is
expressed in QOZHG infected Vero cells, although at greatly reduced levels compared to
a vector with no manipulation of the ICP22 gene or promoter (d120).  No ICP22
expression was found in a vector deleted for that gene, TOZ.  Greater levels of ICP0
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expression were also seen by Northern blot with QOZHG than TOZ, most likely due to
ICP22 expression.  An early gene, gB, which should not be expressed without ICP22,
was also seen with QOZHG but not TOZ.  These viral gene transcription results were
enough to obviate the development of a GFP expressing TOZ vector, named TOZHG.
3.2.7  HSV-1 Vector Development
The two major problems encountered by the use of QOZHG were found to be
toxicity and length of transgene expression.  The results of gene expression analysis
suggest a TOZ background vector (Figure 13) is an appropriate choice to reduce vector-
associated toxicity while allowing the HCMV promoter to be active upon transduction.
The TOZ background vector is completely deficient for ICP4, ICP22, ICP27, UL41, and
UL24.  The disruption of UL24 is the result of a promoter change for UL23, thymidine
kinase-TK.  The original early promoter of TK has been replaced with the IE promoter of
ICP4.  TOZ expresses the lacZ reporter gene in the identical locus as QOZHG does.
The possibility of increased length of transgene expression may be possible through
the use of the herpesviral latency promoter.  The Glorioso lab has previously developed
and shown that the latency associated promoter 2 (LAP2):transgene system works well in
culture and also in vivo.  In neurons, LAP2 and chimeric LAP2:HCMV promoter systems
have demonstrated long-term transgene expression(228,229).  In order to make a systematic
comparison, TOZ vectors were developed that contain either the LAP2:GFP,
HCMV:GFP, or LAP2:HCMV:GFP expression constructs in the ICP27 locus (Figure
13), the same location that QOZHG contains HCMV:GFP.
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Figure 13.  Diagram of promoter construct panels developed in the HSV-1 TOZ.1
background vector.
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One of the ultimate goals of the lab is to transduce CD34+ cells that will deliver
the vector to tumor sites through homing and differentiation into angiogenic endothelium.
Since the best vector currently available, considering both toxicity and expression, is
TOZ, a vector with that background was used for introducing the endothelial specific
promoter, von Willebrand factor.  The new vectors contain vWF:GFP and
LAP2:vWF:GFP expression cassettes in the ICP27 locus (Figure 13).  Comparisons can
now be made with this panel of vectors by transducing, Vero, HUVEC, and CD34+ cells
to determine toxicity, length of transgene expression, and tissue specific expression.
3.3  Discussion
The delivery of therapeutic genes to human stem cells has considerable potential
for the treatment of a variety of genetic and acquired diseases.  An ability to efficiently
transfer genes to stem cells ex vivo without extensive cell manipulation or stimulation and
to direct the expression of therapeutic gene products upon re-implantation into the patient
is essential for successful therapies.  Transduction of stem cells using viral vectors has
met with varying levels of success, with limitations apparently related to both the biology
of stem cells and the properties of the vectors used.  In this context, we have determined
the best conditions for transduction of unstimulated, minimally manipulated CD34+ stem
cells derived from human umbilical cord blood by a replication-defective HSV-1 vector
and have examined the involvement of cellular receptors for the HSV glycoproteins gB,
gC, and gD.
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A range of transduction efficiencies has previously been reported for human stem
cells exposed to different HSV vectors.  For example, nearly 100% transduction without
vector-associated toxicity was reported for bone-marrow derived CD34+ cells using an
HSV-2 single-cycle replicating vector at MOIs of 2-20(89).  These experiments involved
culturing of the stem cells on a stromal support supplemented with serum and exposure to
virus for 2 hours.  Likewise, another study reported 99% transduction of IL-3 and IL-6
stimulated CD34+-mobilized peripheral blood stem cells following incubation with a
replication-defective HSV-1 vector at an MOI of 3(195).  However, only 10% of a similarly
selected population of CD34+ stem cells cultured in serum with or without cytokine
stimulation were transduced in a study using a replication competent HSV-1 vector and a
2 h period of virus adsorption(216).  The variations in these results may be attributable to
differences in infection protocols and detection procedures as well as the handling and
conditioning of the cells, including treatment with cytokines.  This study was conducted
to standardize conditions for infection of unstimulated cells for maximum preservation of
stem cell characteristics.  A vector was used for these experiments that is replication
defective and displays minimal cytotoxicity on a variety of cell lines due to a
combination of impaired immediate-early synthesis of the IE products ICP22 and ICP47
and deletion of the ICP4 and ICP27 IE genes.
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We observed that increasing the virus adsorption time from 1 h, commonly used
for infection of cell lines used to propagate HSV (e.g.Vero cells), to 16 h more than
doubled the number of transduced CD34+ cells at an MOI of 30 (Figure 3A).  These
conditions routinely yielded 65% transduction or more for individual cord blood stem cell
preparations, with levels as high as 85% recorded.  Since the cell isolation and infection
protocols were standardized and the virus lot the same in each instance, this variability
may reflect differences in the quality of primary human cell sources and perhaps genetic
differences among the cell donors.  It is likely that the differences in relative abundance
of the four gD receptor-bearing subpopulations noted between individual stem cell
preparations may also play a role, whether these are rooted in environmental or genetic
variations.
The observations of slow infection kinetics and incomplete transduction of stem
cell populations were further explored by experiments examining the presence of HSV
receptors on these cells.  Infection was inhibited by dextran sulfate, indicating that the
cells were not substantially defective in the synthesis of GAGs, the targets of initial virus
attachment via gB and gC.  Following primary attachment, HSV infection requires
interaction of gD with cell-surface receptors which initiates fusion of the virus envelope
with cell membranes resulting in virus entry.  One or both of two common gD receptors,
HveA and HveC, were identified on the surface of a great majority (94-95%) of the cells
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in independent stem cell preparations, suggesting that most of the cells had both primary
and secondary HSV receptors.  However, since the cell populations were not
homogeneous with regard to HveA and HveC expression, it is possible that the different
receptor-bearing subpopulations differed in their susceptibility to HSV infection.
We observed that 57% and 68% of the cells expressed both gD receptors while
5%-6% lacked both and the remainder carried one or the other.  The maximum infection
figure of 85% was in the range of the total fraction of gD receptor-bearing cells (94-95%)
although the routine figure of 65% infection suggested that a portion of the infected cells
may have escaped detection due to inadequate expression of the reporter GFP gene;
alternatively, a portion of the receptor-positive cells was HSV resistant.  A report
comparing expression of GFP in CD34+ cells from adenoviral vectors containing
different promoters and polyadenylation signals found the PGK-1 promoter increased
both GFP expression and transduction levels when compared to a similar vector utilizing
the HCMV promoter(230).
Infection reached nearly 30% after a 1 h adsorption period, but barely increased
when the adsorption time was doubled.  Infection appeared to accelerate again when the
virus was left with the cells for 2-5 hrs, but gains in infected cell numbers per additional
hour of adsorption time were modest after this period although relatively stable to at least
16 hours.  This result raises the possibility that different subpopulations of cells were
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infected at different rates.  For example, a nearly half-maximal level of infection was
reached with just 1 h of virus incubation, which could correspond to the fraction of cells
displaying both HveA and HveC; likewise, it is possible that HveA-positive cells were
not infected at the same rate as HveC-positive cells.  It is also possible that one of the
subpopulations was largely resistant to infection, as suggested by the observations that (i)
antibodies to HveC did not noticeably inhibit infection, (ii) only 40% of the cells became
infected in an experiment where 80% of the cells lost detectable surface expression of
HveC upon incubation with virus, and (iii), as already mentioned, the percentage of gD
receptor-positive cells was generally larger than the fraction of cells that could be
detectably infected.  It may be hypothesized from these results that contact between the
virus and HveC on stem cells generally results in internalization of the virus:HveC
complex into a non-productive intracellular compartment rendering the HveC-positive
subpopulation largely resistant to HSV.  This hypothesis is consistent with our previous
results demonstrating internalization and degradation of a virus targeted to a non-
traditional HSV receptor such the erythropoietin(231) or VSV-G(232) receptor.
An alternate explanation for this result is that binding of virus to HveC initiates
receptor cycling in both infected and non-transduced cells.  Similar results have been
reported in other virus systems where binding of the viral glycoproteins results in the
cycling of one receptor but not another(233-235).  The lab is currently exploring the effects of
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gD binding to HveC with respect to activation of cellular functions that may ultimately
aid in priming of the host cell for virus replication.
Due to toxicity and short-term transgene expression in vitro by the QOZHG
vector, it was needed to develop new vectors in order to further study gene transfer to
CD34+ cells.  Vectors were developed within the exisiting TOZ background in which
HCMV, LAP2, or LAP2:HCMV promoter:GFP constructs were introduced.  These
constructs will be compared by transducing CD34+ cells, examining cell survival, and
monitoring length of GFP expression in order to determine the appropriate vector for
future work.  Similarly, vectors were developed containing the endothelial specific
promoter vWF or the chimeric LAP2:vWF promoters with GFP.  These constructs were
developed to determine if endothelial specific transgene expression is possible in the
HSV background and could prolonged expression be gained by the chimeric promoter.
Lastly, this study has shown that CD34+ cells transduced with a vector containing
an HCMV:EPO expression cassette (MOI=30) produced high levels of EPO in culture
supernatant (600 mIU/mL) at 6-7 days post infection.  This model represents another
potential clinically relevant application for HSV transduced CD34+ cells.
3.4  Conclusions and Future Work
This work has demonstrated that 93%-95% of CD34+ cells possess one or both
herpesviral fusion receptors, that they are functional, and that 65% of the cells were
transduced at MOI=30 by the vector QOZHG after 16 hours of adsorption.  Although
these results are promising, further studies indicated that the vector was highly toxic to
the cells and resulted in limited in length of transgene expression in vitro.  The ability to
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develop a vector that is able to efficiently infect CD34+ cells with low toxicity and
extended or tissue specific transgene expression is crucial in the future applications of
this project.  A panel of vectors has been developed that represent the best current
herpesviral vector technology for achieving these requirements.
Once the appropriate vector is determined, transduced stem cells may then be
investigated for the potential to induce anti-angiogenesis in an animal tumor model.
Infected and uninfected stem cells can be infused into mice to verify cell homing to
angiogenic sites, differentiation into endothelial cells, and expression of herpes thymidine
kinase (TK).  If the infected cells are found to be present at the tumor site, GCV killing
will be attempted with vWF:TK and/or ICP4:TK vectors.
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4.0  PRODUCTION OF HSV-1 VECTORS
4.1  Introduction
Now that it is established that CD34+ cells can be transduced with HSV-1 vectors,
many questions regarding the infection process, gene expression, and cell differentiation
should be further examined.  However, for all these studies, significant amounts of highly
purified vectors are needed, particularly if one notes that it is more difficult to produce
high titers and maintain low contaminant protein levels of TOZ background vectors due
to its more disabled genome, in comparison to QOZHG.  Thus the optimization and
scale-up of vector manufacturing processes is vital for further research and eventual
application of gene therapy using HSV-1 vectors.  Because of the importance of
production and purification of the vectors, I examined several issues for developing
efficient production and purification schemes.
Replication-defective HSV-based viral vectors deleted for one or several essential
immediate-early (IE) regulatory gene products can be propagated in vitro in
complementing cell lines engineered to express the missing essential functions resulting
in virus replication(109) and ultimately lysis of the host cell.  Vector-associated
cytotoxicity in non-complementing cells is minimized through deactivating the cytotoxic
immediate early genes in the HSV-1 vector(75-78,138,218,236).  The progressive deactivation
of the HSV-1 regulatory genes not only progressively reduces the cytotoxicity of the
virus, but it also reduces vector yield.  For example, the yield achieved with replication
defective vectors deleted for multiple IE genes is only about 0.1% of that obtained using
wild-type virus.  Hence, it is difficult to obtain sufficient amounts of high quality vector
stocks.
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The HSV-1 vectors currently employed in clinical trials(237,238) are replication
competent and minimally deleted for the gene γ34.5, which is involved in
neurovirulence(239-242), and hence do not face such production issues.  This is also the case
for DISC-HSV-2 vaccine vectors(89,243,244) that are deficient only in the binding and/or
entry protein, glycoprotein H (gH).  However, even these minor alterations to the HSV
genome result in viral recombinants that are more difficult to grow and purify compared
to wild-type virus.  Thus, obtaining highly purified high titer vector stocks is one of the
major obstacles remaining in the use of viral vectors for human clinical trials.
In a previous publication(245), another graduate student and I examined the
interative infection parameters of cell number, multiplicity of infection, and metabolism
with the goal being to optimize these culture conditions.  The results were used for scale-
up production using a Corning CellCube bioreactor.  It was found that allowing cell
growth to reach near or over confluent conditions, infecting at MOI=0.02, and perfusion
of medium at 24 hours post infection result in efficient production of vector.  Additional
parameters that may affect vector harvest due to viral stability and production were
studied and will be presented here.
To further improve the vector yield, I examined the effect of temperature and
media conditions on the stability of an HSV-1 vector, and the resulting production of the
vector by cells cultured at lower temperatures.  The results reveal that HSV stability is
2.5-fold greater at 33°C than at 37°C and is further stabilized at 4°C.  Additionally, a
significantly higher half-life was measured for the vector in infection culture conditioned
serum medium compared to fresh medium with or without serum.  Synchronous
infections incubated at 33°C produced 2-fold higher amounts of vector than infected cells
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incubated at 37°C, but with a lag of 16-24 hours.  Vector yield was 3-fold higher and
remained stable at peak levels for a longer period of time in cultures incubated at 33°C
than 37°C.  A pronounced negative effect of increased cell passage number on vector
yield was also observed.  Vector production at 33°C yielded similar levels regardless of
passage number but was reduced at 37°C as passage number increased.  Together, these
results contribute to improved methods for high titer HSV vector production.
4.2  Results
4.2.1  Comparison of Temperature, Medium, and pH on Vector Stability
Infectivity and/or stability of enveloped virions has been shown to be affected by
various conditions such as medium components, pH, and temperature(246-253).  It has been
shown that thermal or pH inactivation of HSV results in particles that have a slightly
increased density compared to untreated virus(254,255).  Inactivated particles were found to
retain the ability to adsorb to the surface of cells but were greatly reduced in productive
entry(254,256).
Figure 14 shows the effect of temperature on stability of the vector at 37°C, 33°C,
and 4°C in various media.  An average half-life for each temperature and medium
condition was calculated assuming first order kinetics using the trend-line equation
determined using Excel.  The calculated half-lives of 21.8 hours, 8.8 hours, and 6.7 hours
for infection culture conditioned serum medium, fresh serum containing medium (10%),
or fresh medium without serum, respectively, were determined at 37°C (Figure 14A).
The virion half-life was extended ~2.5-fold (59.2, 22.4, and 15.1 hours in infection
culture conditioned medium, fresh medium with serum, or fresh medium without serum,
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Figure 14.  Effect of temperature, medium, and pH on vector stability.
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 respectively) when incubated at 33ºC (Figure 14B) compared to incubation at 37°C.
Viral stability was further increased at 4°C (Figure 14C) with half-lives of 182.4 and 32.6
hours in fresh serum medium and fresh medium without serum, respectively.  The decay
rate was insignificant for vector in infection culture conditioned serum medium, at 4°C.
Since pH has been also proven to affect vector stability, this was next examined.  Pelleted
vector was resuspended in serum medium buffered with HEPES and adjusted to pH
values of 6.8, 7.4, or 8.0.  These values were chosen as representative of the range which
can be found in infection cultures at various times of the process.  Figure 14D shows that
HSV vector is most stable in pH 6.8 with decreases in stability as pH increases.  Together
the combined results of Figure 14 demonstrate that HSV-1 has increased stability at
lower temperatures, in serum medium that has been conditioned by productive infection,
and at lower pH values.
4.2.2  Effect of Lower Temperature on Complementing Cell Growth
Since vector stability increased ~2.5-fold when the incubation temperature was
reduced to 33°C, regardless of incubation medium, we next examined the effects of
temperature on cell growth.  For this, cells passaged at 37°C were subcultured and
incubated at 37°C or at 33°C.  Duplicate flasks were harvested for each temperature over
time and viable cell counts performed.  The growth curves (Figure 15) yielded doubling
times of 22 hours and 32 hours for cells growing at 37°C and 33°C, respectively,
calculated using the data points from 24 to 96 hours post plating and assuming first order
kinetics.  In addition to a slower growth rate, the cells cultured at 33°C plateaued at a
lower final cell density (2.0×106 vs. 3.5×106).
79
Figure 15.  Effect of temperature on cell growth.
Figure 16.  Intracellular and extracellular virus production for synchronous infections
incubated at 33°C and 37°C.
Hours Post Plating
C
el
l N
um
be
r
1x105
1x106
1x107
0 50 100 150 200 250
33ºC: tD=32 hours
37ºC: tD=22 hours
Hours Post Infection
P
F
U
/C
el
l
0
5
10
15
20
25
30
0 20 40 60 80 100
33ºC Intra-cellular
37ºC Extra
37ºC Intra
33ºC Extra
80
4.2.3  Comparison of Vector Production from Synchronous Infection at Lower
Temperature
Since the lower temperature did not dramatically alter cell growth, vector
production was also examined at this lower temperature (33°C).  Initial infections were
conducted at a high multiplicity of infection (MOI=5.0) to ensure synchronous
production, although actual vector production is normally conducted at a much lower
MOI (0.01-0.05).  This should result in minimal impact from secondary infections and
thus enable us to assess the time it takes for the virus to be both produced and released
into the culture as well as the number of vector particles produced per cell (burst size).
Cells cultured at 37°C were sub-cultured, mixed with virus, and incubated at 37°C or
33°C and the number of virus particles produced determined by standard plaque assays.
We observed a 2-fold increase in virus production, both intracellular and extracellular, at
33°C compared to the standard temperature of 37°C (Figure 16).  The peak of
intracellular virus production and the release of extracellular virus occurred 16-24 hours
earlier at 37°C than at 33°C.  The vector decay in the supernatant appears to be faster at
37°C, which was not unexpected based on the decreased half-life at that temperature
(Figure 14).  Since the burst size, or PFU per cell, was delayed but significantly higher at
33ºC, production schemes using lower MOI involving a temperature shift were examined.
4.2.4  Effect of Temperature and Cell Passage Number on Viral Production
We set out to investigate the ability to obtain high titer virus stocks by shifting
temperature between the cell growth phase (37°C) and that of virus harvest (33°C) based
on our previous results (Figures 14 and 15).  These experiments were conducted at an
MOI of 0.05, which is normally used for the propagation of this vector.  Cells previously
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cultured at 37°C were infected and incubated at 37°C for the first 24 hours, after which
time some plates were shifted to 33°C.  The supernatants were sampled over time for
determination of the number of infectious extracellular viral progeny produced (Figure
17).  The reason for the delay in temperature shift was to maximize secondary infection
occurring during the first 24 hours at 37°C in combination with increased vector release
and stability at 33°C.
Complementing cells are continuously passaged usually in the absence of drug
selection due to expense and reduced growth rate.  We had previously observed that cell
passage number played some role in vector production.  In order to determine the effect
of cell passage on the production of vector, infections were performed on high passage
cells (Figure 17).  The transfer of infected cultures to 33°C resulted in a 3-fold increase in
vector concentration in the supernatant for low passage (30) cells (Figure 17A).  As the
passage number increased, the difference in vector levels became 4- and 10-fold higher at
passages of 45 (Figure 17B) and 80 (Figure 17C), respectively.  The increased difference
in vector concentration came at the expense of the infection cultures that remained at
37°C, as the production levels remained near constant at 33°C regardless of passage.
Similar results were also obtained if the shift to 33°C was made immediately after
infection instead of at 24 hours post infection, except that the peak in virus production
exhibited about a 24-hour lag (data not shown).  It was observed that when titering the
same vector stock, developing plaques are smaller and ~50% less in number for high
passage cells compared to low passage cells.
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Figure 17.  Effects of temperature and cell passage number on production of HSV vector.
Figure 18.  Effect of virus infection on extracellular glucose and lactate levels.
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4.2.5  Effect of Passage Number on Cell Metabolism
A possible explanation for the difference incurred by higher passage cells may be
due to variation in primary glucose metabolism.  To see if there are substantial variations
in cell metabolism as a function of passage number, glucose consumption and lactate
formation were measured for cells of 30 and 80-passage numbers.  Cells were infected at
MOI=0.05, as in the previous production experiments, and supernatant samples removed
over time.  A substantially higher rate of glucose utilization and lactate formation was
observed for the longer-passaged cells (Figure 18).
4.3  Discussion
The ability to produce and purify high levels of replication-defective viral vectors
is a major limiting factor for the advancement of human gene therapy clinical trials.  In
prelude to use of a bioreactor, we examined the effects of varying two infection
parameters, cell number and initial vector amount added (MOI), as well as examining the
infection culture metabolism.  These results were used to develop a scheme for use with
the Corning CellCube bioreactor for production of two vectors, QOZHG and TOZ.  The
results showed that vector produced/surface area, compared to that obtained from small-
scale tissue culture flasks, can be attained in the bioreactor system.  There are several
additional parameters that, when optimized, may result in increased levels of vector
production.
One important viral property that can have a significant impact on vector harvest
is stability, which is affected by several conditions.  A study of the effect of temperature
and medium on HSV vector stability revealed increased half-life at lower temperatures
(33°C and 4°C) and in conditioned serum containing medium.  From a scale-up
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standpoint, the increased stability at 33°C may translate into increased vector yield during
production by a thermal shift from 37°C to 33°C.  The lack of virion decay at 4°C in
conditioned medium can be beneficial once the virus is harvested from the production
infection during large-scale vector production.  Since purification schemes often have
lengthy processing times, significant vector loss resulting from medium or temperature
related instabilities can be minimized by using conditioned medium and placing the
samples at 4°C.  The increased stability of conditioned serum medium compared to fresh
serum medium may be partly explained by pH.  The pH of the conditioned medium was
about 0.4 pH units lower than that of fresh medium (6.9 vs. 7.3).  Since the virus tends to
be more stable at slightly acidic pH in culture medium(249), the half-life differences we
have observed in the two media may be partly related to these variations.  The presence
of serum (10%) in the medium was found to increase the stability in comparison to
medium without serum.  In addition, we have previously reported experiments in which
individual protease inhibitors or a protease inhibitor cocktail added to the virus culture
did not aid in vector stability in infection culture conditioned medium(257).
In order to determine the effect of reduced temperature on complementing cells,
initially cell growth was monitored at 33°C and 37°C.  Cells cultured at the reduced
temperature displayed a 50% longer doubling time and achieve a 40% lower final
density.  Viral production on a per cell basis at both 37°C and 33°C using high MOI
synchronous infections showed a 2-fold increase in vector concentration at 33°C with a
delay of 16-24 hours.
When applying this observation to typical vector production conditions
(MOI=0.05), the transfer of infected cell cultures from 37°C to 33°C demonstrated
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significantly increased vector production.  The reduced temperature resulted in 3-fold
higher levels of vector yield with cells of low passage (p30).  This difference increased
(4- and 10-fold) as passage number increased (p45 and p80).  Another important
observation is that the high levels of extracellular vector produced remained constant
over a longer period of time and at each passage when the culture temperature was
reduced to 33°C.  This is most likely a coordinated effect between the higher production
level (Figure 16) and the increased virus half-life (Figure 14).  This observation will have
a dramatic impact upon scale-up production by making the selection of harvest time less
critical than it would at 37°C, where the failure to harvest at the proper time results in
dramatically decreased yields.
The higher HSV vector production levels achieved at the lower temperature of
33°C are in accord with the reports on retrovirus vectors(247,248,252).  To our knowledge,
this is the first report on the effect of passage number on vector yield at different
temperatures, and only limited data exist on the effect of long-term culturing on cell
growth, metabolic, and genetics changes.  However, a recent work with insect cells
revealed some insights into cell growth and recombinant protein production in the insect-
baculovirus expression system(258).  Early passage cells grew to a 2- to 3-fold higher cell
density and displayed higher levels of recombinant protein production.  In addition, the
older-passaged cells grew to a lower density, although the cells showed a shorter lag
phase and about 20% faster growth rate initially.  Hence, higher rates of glucose
consumption and lactate formation may indeed lead to a lower final cell density, higher
initial growth rate, and perhaps even a shorter lag time.  Thus, it is possible that the
higher glycolytic activities displayed by the Vero cell cultures in Figure 18, are the
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common characteristics of longer-passaged cells of different origins and may contribute
to decreased vector production at 37°C.
4.4  Conclusions and Future Work
In order to meet increased demands of high titer HSV vector stocks, we have
efficiently scaled-up production from roller bottle flasks to a 21,250 cm2 Corning
CellCube bioreactor(245).  Additional studies aimed at increasing vector harvest
demonstrate a significantly longer virus half-life at 4°C or 33°C than at 37°C, as well as
increased vector stability in conditioned culture medium compared to the fresh medium
with or without serum.  The application of these parameters can be tested in the
bioreactor for additional increases in vector producton levels.  A second biorector system,
the New Brunswick CelliGen+, is an alternate configuration that utilizes microcarriers to
increase surface area while requiring low volumes of media.  This is an interesting
system that may prove to be a better configuration.
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5.0  PURIFICATION OF HSV-1 VECTORS
5.1  Introduction
The U.S. Food and Drug Administration (FDA) sets limits on the amounts of
contaminant protein and DNA present in biologically derived drugs.  These amounts vary
depending on the type and application of drug as well as the required dosage.  For
example, current clinical vaccine preparations are required to contain less than 100 µg
complementing cell protein and 10 ng DNA per dose(259).  These limits have not yet been
established for replication-defective herpes vectors and thus will need to be set by our lab
when we approach the clinically relevant manufacturing stage and require FDA approval
of our product.  The limits set for vaccines are a reasonable guideline in which to
compare developed purification schemes.
In order to study and design a vector separation system, it is imperative to
understand the production process.  The productive infection of HSV results in lysis of
the cells and release from the surface they were adhered to.  In addition, the culture
medium contains 10% fetal bovine serum that cells require in order to produce high
levels of vector.  Thus the vector production process results in a slightly viscous slurry of
cell debris, virus, DNA/RNA, and proteins.  Since HSV is an enveloped virus, its ability
to infect cells is compromised by damage to this lipid membrane, so vector stability
issues must also be considered in developing a purification process.
In current lab purification techniques, the entire infection culture is harvested and
centrifuged at low speeds (1,000×g) to clarify the virus from cell debris.  This supernatant
is then centrifuged at high speeds (13,000-48,000×g) to pellet virus from small debris,
protein, and DNA molecules.  The viral pellet is resuspended in a small volume and
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loaded onto a density gradient which separates infectious virions from remaining debris
such as cell organelles, defective viral particles, and empty capsids.  The fraction
containing the majority of infectious vector is removed and centrifuged at high speed to
pellet the virus again in order to perform a buffer exchange out of the density gradient
solvent and into a phosphate buffered saline solution.  The benefits of this protocol are
that concentration is high and it is technically easy to perform.  The disadvantages of this
process include significant vector losses and clumped vector particles due to forces of
centrifugation, and requirements for extensive personnel handling, which increases the
chances for contamination.  In addition, this process may not prove to be efficiently
scalable.  These disadvantages motivated us to develop new processes that would be
more efficient, require less handling, and be scalable.  Efficiency and scalability are
critical factors as highly purified vectors are needed for assessing their efficacy in clinical
trials.  Certainly, if gene therapy becomes a widespread treatment or preventative tool in
medicine, the amounts of vector reqired will increase dramatically.
Several reports describe the purification of vectors, including retrovirus,
adenovirus, adeno-associated virus, and herpesvirus by vector size, density, and/or
affinity(259-268).  Based on these works, and with our goal being to attain contaminant
levels near that of vaccines while maintaining high levels of vector recovery, current lab
purification procedures were examined and alternate down-stream strategies were
investigated.
A two-stage filtration process is proposed.  Vector preparation is first separated
from larger particles such as cell debris by a larger filter size, followed by a smaller size
filter for removal of smaller particles.  Tangential-flow filtration was selected to
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minimize membrane fouling.  These two filtration steps should partially purify and
concentrate the vector.  Heparin ion exchange/affinity chromatography(259) was adapted
for the next step following filtration.
Initially upon infection, HSV glycoproteins gB or gC bind to cell surface heparan
sulfate glycosaminoglycans through a charge interaction.  Trybala, et al.(260) have
demonstrated that the presence of sodium chloride or heparin negatively affects the
ability of HSV to bind to cells in culture.  Thus heparin chromatography columns can be
used to bind the virus and sodium chloride can be used to elute the vector.
In this chapter, results of my work using the standard centrifugation process are
first presented.  These results are then compared with the new process of filtration and
chromatography that I developed.  The results demonstrated that the combined filtration
and chromatography steps proved superior to the standard centrifugation protocol.  The
virus recovery was high in this process and greater than 99% of DNA and proteins were
also removed.
5.2  Results and Discussion
5.2.1  Analysis of Vector Centrifugation
First the recovery yield using a standard centrifugation protocol was examined.
In the centrifugation protocol, after infection and lysis of the cells, the entire infection
culture was harvested and pooled.  The cell debris was separated from virus by
centrifugation at low forces of 1000×g.  This initial step resulted in the loss of 50% of the
virus (data not shown).  This dilute vector solution is then subjected to high force
centrifugation to pellet the virus.  In order to examine the efficiencies of vector pelleting,
this step was repeated using various centrifugation forces and lengths of time.  Vector
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supernatant was centrifuged at either 13,000×g, 27,000×g, or 48,000×g for 10, 20, or 30
minutes, at 4ºC.  The presence of virus was then examined in both the supernatant and the
resuspended pellet.  Figure 19 shows the results of the best recoveries for each centrifugal
force (all 30 minute times).  The highest recovery of vector in the pellet, 50%, was found
in the preparation treated at highest force.  For all three cases, 40% of the virus was
unrecoverable after examining both the pellet and the supernatant.  Considering that the
process is performed twice, once before and once after the gradient, this dictates that 25%
(0.5 × 0.5) is the maximal recovered virus from these steps.  The density gradient
procedure, which has been previously optimized by the Glorioso lab, results in recoveries
of up to 80% of infectious virus (data not shown).  Thus the overall centrifugation
process can result in optimal recoveries of 0.5 ×  0.8 × 0.5, or 20%, with volume
concentration factors greater than 50×.  However, if one also considers the very first
centrifugation step for settling the cells (50% loss), then the overall yield of recovery
would reduce to 10%.  Recoveries of new purification strategies were next studied with
the goal being to increase recoveries but maintain comparable concentration factors.
5.2.2  Initial Experiments Using Various Filter Sizes
Our lab and others have shown that by electron microscopy analysis individual
virions are approximately 200 nm in diameter.  During virus replication the cells lyse and
some virions may remain associated with cell membrane or debris, or other virions.  This
may result in discrepancies when attempting to filter the virus by various pore sizes.  In
order to determine actual production vector size, infections were initially harvested and
separated from cell debris by centrifugation.  Vector preparations were filtered through
syringe filter membranes using pore sizes ranging from 1.2 µm down to 0.22 µm.  Figure
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Figure 19.  Effect of centrifugation force on vector purification.
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20A shows that greater than 85% of the virus passes through filter sizes of 1.2, 0.8, or
0.65 µm, but only 25% and 1% pass through a 0.45 or a 0.22 µm pore, respectively.
Based on the virus size of about 200 nm we expected a higher passage of vector
through the filters, in particular for 0.45 µm.  It was felt that it is likely vector
aggregation may lead to formation of larger particles which are excluded from the filter.
Electron microscopy experiments revealed (Figure 20B) that indeed there is some
aggregation of vector present in our sample.  Thus at least some loss or exclusion of
vectors from the filter may be attributed to their aggregation.
To remove proteins and other macromolecules, filtrate from large pore-size filters
were loaded onto a 300,000 molecular weight cut-off Centricon centrifugal filter system.
Figure 20C shows that 60%-85% of the virus was recovered.  These initial dead-end
filtration techniques demonstrate the potential to purify and concentrate virus by
filtration.  The use of a tangential-flow filtration system may minimize vector losses
associated from gel layer formation or pore plugging that occurred in this system.
5.2.3  Initial Heparin Chromatography for Vector Purification
Initial studies were performed to examine the ability of HSV-1 to bind to the
heparin column and verify what NaCl concentration elutes the vector.  Vector was loaded
to the column and the vector concentration in the effluent was determined.  The vector
was eluted with 5 column volumes each of 0.5 M, 1.5 M, and 3.0 M NaCl in PBS, pH
7.0.  Nearly 70% of the bound vector eluted in the 0.5 M NaCl, 30% in the 1.5 M NaCl,
and 2% in the 3.0 M NaCl as shown in Figure 21A.  Additional analyses indicate that
90% of total protein was eliminated during vector loading (Figure 21B).
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Figure 20.  Effect of filter pore size on vector passage and retention.
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Figure 21.  Heparin cromatography column HSV-1 vector purification.
Figure 22.  Schematic of QuixStand tangential-flow filtration system.
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5.2.4  Combined Tangential-Flow Filtration and Heparin Chromatography Vector
Purification
I next examined the combination of filtration and chromatography steps for the
purification and concentration of HSV-1 vectors.  A tangential-flow filtration system
(Quixstand system from A/G Technology) shown in Figure 22 was used in the
experiments.  The system has a feed reservoir, a recirculation  pump, a filter cartridge,
inlet and outled pressure gages,  a port for permeate collection, and a recirculation line.
Pump speed and direction can be controlled by the system, along with the permeate
collection rate by adjusting filter outlet pressure or attaching a second pump for permeate
control.  Retained product can be harvested by use of a retentate port located at the base
of the feed reservoir.  Three different pore size filtration cartridges were studied with this
system.  The larger two sizes 0.8 µm and 0.65 µm are designed to allow vector passage
but retain cell debris.  The smaller size of 0.1 µm is designed to retain and concentrate the
vector while passing smaller debris. Vector was produced in roller bottles and after cell
lysis the harvests, 2 liters, were used as the initial virus preparation.  One liter of the
harvest was processed initially by either a 0.8 µm or a 0.65 µm filter as described in
Materials and Methods.  The permeate of each system was then processed separately by a
0.1 µm filter.  The vector stocks were concentrated to 200 mL and washed with PBS to
perform a buffer exchange in preparation for heparin chromatography.  Both filter
purified vector stocks were separately loaded onto heparin columns as described in
Materials and Methods.  Weakly bound protein was removed by washing with 0.25 M
NaCl and vector was eluted in 0.75 M NaCl.
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Analyses of both systems were made by examining vector recovery, total protein,
and total DNA from samples taken during the processes and displayed in Table 1.
Analysis of the 0.8 µm system shows that the two filtration steps recover 77% (0.9 ×
0.86) of the initial vector.  The 0.65 µm system recovers 61% (0.7 × 0.87) of the loaded
vector.  The chromatography step recovered 75% and 81% of the bound vector after
purification by the 0.8 µm and 0.65 µm filtration systems, respectively.  The overall
vector recoveries were 58% and 49% for these systems.  The vector was concentrated
59× using both filter sizes and final contaminant levels were near identical with removal
of greater than 99% of both total protein and DNA.  It is important to note that the
recovery yield of about 50% in our system is substantially higher than that of the
centrifugation protocol (10%) noted earlier.
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Table 1.  Comparison of combined filtration and chromatography purification systems.
0.8 µm FILTER
0.65 µm FILTER
% VIRUS
RECOVERED
TOTAL
PROTEIN
TOTAL
DNA
STOCK
0.1 µm FILTER
0.1 µm FILTER
90
86
100
TOTAL
VOLUME
1 L
1.5
0.21
1.5 L
0.24
70
87
4.0
0.6
4.3 g 13 mg
0.7
0.28
3.8 g
0.4
0.7 mg
0.25
CHROMATOGRAPHY 75 0.030 0.055 0.0175
CHROMATOGRAPHY 81 0.02 0.05 0.0175
EXPERIMENT #1
EXPERIMENT #2
OVERALL RECOVERY     58
OVERALL RECOVERY     49
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5.3  Conclusions and Future Work
The combined filtration and chromatography system is a highly efficient process
for concentration and purification of HSV-1 vectors.  The overall vector recovery of 50%
is substantially higher than that of the centrifugation based process (10%).  This high
recovery yield is not attained by compromising the concentration factor.  About 60-fold
concentration was achieved for both the centrifugation-based and the filtration-
chromatography process.  Additional benefits of the combined filtration and
chromatography system include minimal personnel handling, which reduces the chances
for errors and contamination while increasing the overall safety by minimizing vector
exposure to technicians, and scalability of the process.
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